Methods for non-invasive monitoring of organ health in cross-species transplantation
By detecting cell-free nucleic acids in transplant recipients and utilizing high-throughput sequencing and digital PCR technologies, taking into account the differences in donor and recipient genome size, the problem of non-invasive detection and monitoring of transplant rejection in cross-species transplantation has been solved, enabling accurate long-term monitoring and treatment.
Patent Information
- Application Number
- CN202380029001.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-21
- Filing Date
- 2023-03-21
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of non-invasive methods in the current technology to detect, predict and monitor transplant rejection status of cross-species transplants, and existing laboratory tests are not suitable for assessing transplant status between different species, resulting in high invasiveness, inaccuracy and difficulty in long-term monitoring.
By detecting cell-free nucleic acids in transplant recipients and utilizing high-throughput sequencing and digital PCR technologies, taking into account differences in donor and recipient genome size, the amount of cell-free nucleic acids from the donor can be determined, enabling the detection of transplant rejection and adjustment of immunosuppressive therapy.
It provides a sensitive, accurate, and non-invasive method for long-term monitoring of graft status in transplant recipients, improving the accuracy and sensitivity of detection and treatment, and is suitable for non-invasive monitoring of cross-species transplantation.
Smart Images

Figure CN118922560A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 322,144, filed on March 21, 2022, which is hereby incorporated by reference in its entirety.
[0003] References to Electronic Sequence Listings
[0004] The contents of the electronic sequence listing (506612003040SEQLIST.xml; size: 21,075 bytes; and creation date: March 21, 2023) are incorporated herein by reference in their entirety. Technical Field
[0005] Provided herein are methods and kits for detecting, predicting, diagnosing and / or monitoring the cross-species transplant status of organs, cells or tissues, and treatment methods related thereto. Background Art
[0006] Transplanting cells, tissues or organs from one species to another in cross-species transplantation or xenotransplantation is a promising solution to the severe shortage of human organs, cells and tissues available for transplantation. However, due at least in part to the possibility of cross-species transmission of infection, immune rejection of transplant recipients and genetic, anatomical and physiological differences between donors and recipients, cross-species transplantation is challenging. Immune rejection of cross-species transplants can be mediated by both acquired immunity and innate immunity in transplant recipients. In some cases, the immune response of the recipient to cross-species transplantation can lead to hyperacute rejection, acute antibody-mediated rejection, acute cell rejection or mixed antibody-mediated rejection and cell rejection. See, for example, Lu et al., "Xenotransplantation: Current Status in Preclinical Research." Frontiers in immunology, Vol. 10, 3060, January 23, 2020. Therefore, in order to prevent or suppress immune rejection of cross-species transplants, it is necessary to suppress the immune system of the recipient medically.
[0007] After transplantation, the graft status in the transplant recipient can be monitored during the remaining time of the recipient's life span, including the immune-mediated rejection of the transplant function and the transplant. In heart transplantation, for example, the monitoring of rejection may include up to 15 scheduled biopsies within the first year of transplantation to provide a myocardial specimen for pathologists to perform histological evaluation. Each biopsy procedure is invasive, stressful, inconvenient, and there is a procedural risk for the patient, and it is expensive. In addition, biopsy sampling is extremely local, so the histological abnormality of any non-biopsy area of the heart will be missed. The grading of biopsy is subjective, and the inconsistency found in biopsy is common between independent pathologists. In addition, biopsy is mainly used to monitor transplant rejection within the first year after transplantation, but this invasive method is not very suitable or established for guiding individualized immunosuppressive therapy over a long period of time (for example, more than one year after transplantation). Clinical laboratory tests have been developed to evaluate the status of allogeneic transplants (i.e., transplants between members of a single species) based on genetic variation within the same species (e.g., single nucleotide polymorphisms (SNPs) or based on polymorphisms of human leukocyte antigen (HLA) genes). However, these laboratory tests may not be applicable or appropriate for evaluating the status of transplants where the donor and recipient are of different species.
[0008]
[0006] Therefore, a need exists for improved non-invasive methods of detecting, predicting, diagnosing and / or monitoring cross-species graft status in transplant recipients, as well as methods of determining the need to administer or adjust immunosuppressive therapy administered to transplant recipients of cross-species transplants. Summary of the invention
[0009] In one aspect, the present invention provides a method for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising a cell-free nucleic acid derived from the donor and a cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and the generated sequence reads are mapped to at least the donor-specific genomic sequence, wherein the difference in genome size between the donor and the recipient is taken into account; and c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected. In some embodiments, the method further comprises adding a quantitative spike nucleic acid control to the sample in step a, wherein the sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid. In some embodiments, the determination step comprises mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences. In some embodiments, sequencing reads are generated from regions of a selected size of the genome. In some embodiments, the size difference between the donor genome and the recipient genome is accounted for by utilizing the average coverage of a region of a selected size across the genome, wherein the region is large enough to have sufficient coverage, and wherein the background noise is low enough to distinguish between the donor and recipient genomes. In some embodiments, the size of the region is at most 1M bases, at most 10M bases, or at most 100M bases. In some embodiments, the amount of the donor-derived cell-free nucleic acid is the average coverage percentage of a region of a selected size across the genome, wherein the region is large enough to have sufficient coverage, and wherein the background noise is low enough to distinguish between the donor and recipient genomes. In some embodiments, the high-throughput sequencing assay includes a next-generation sequencing assay.
[0010] In another aspect, the present invention provides a method for treating transplant rejection in a recipient of a transplant from a donor, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and mapping the generated sequence reads to at least the donor-specific genomic sequence, wherein the difference in genome size between the donor and the recipient is taken into account; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) based on the amount of donor-derived cell-free nucleic acid, immunosuppressant therapy is administered to the transplant recipient. In some embodiments, the method further comprises adding a quantitative spike nucleic acid control to the sample in step a, wherein the sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid. In some embodiments, the determination step comprises mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences. In some embodiments, sequencing reads are generated from regions of a selected size of a genome. In some embodiments, the size difference between the donor genome and the recipient genome is accounted for by utilizing the average coverage of regions of a selected size across the genome, wherein the region is large enough to have sufficient coverage, and wherein the background noise is low enough to distinguish between the donor and recipient genomes. In some embodiments, the size of the region is at most 1M bases, at most 10M bases, or at most 100M bases. In some embodiments, the amount of the cell-free nucleic acid of the donor source is the average coverage percentage of regions of a selected size across the genome, wherein the region is large enough to have sufficient coverage, and wherein the background noise is low enough to distinguish between the donor and recipient genomes. In some embodiments, high-throughput sequencing assays include next-generation sequencing assays.
[0011] In another aspect, the present invention provides a method for adjusting immunosuppressive therapy in a recipient of a transplant from a donor, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and mapping the generated sequence reads to at least the donor-specific genomic sequence, wherein the difference in genome size between the donor and the recipient is taken into account; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) based on the amount of donor-derived cell-free nucleic acid, immunosuppressant therapy applied to the transplant recipient is adjusted. In some embodiments, the method also includes adding a quantitative spike nucleic acid control to the sample in step a, wherein the sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid. In some embodiments, the determination step includes mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences. In some embodiments, sequencing reads are generated from the region of the selected size of the genome. In some embodiments, the size difference between the donor genome and the recipient genome is taken into account by utilizing the average coverage of the region of the selected size across the genome, wherein the region is large enough to have enough coverage, and wherein the background noise is low enough to distinguish the donor and recipient genomes. In some embodiments, the size of the region is at most 1M bases, at most 10M bases or at most 100M bases. In some embodiments, the amount of the cell-free nucleic acid in the donor source is the average coverage percentage of the region of the selected size across the genome, wherein the region is large enough to have enough coverage, and wherein the background noise is low enough to distinguish the donor and recipient genomes. In some embodiments, high-throughput sequencing determination includes next-generation sequencing determination.
[0012] In another aspect, a method for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by digital PCR assay, wherein the amount of donor-derived cell-free nucleic acid is determined by reference to the amount of the analyzed sample, or by digital PCR quantitative determination of donor-specific nucleic acid and recipient-specific nucleic acid as the ratio of donor-derived cell-free nucleic acid to total donor-specific and recipient-specific nucleic acid; and c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected. In some embodiments, the digital PCR assay comprises one or more single-plex digital PCR assays. In some embodiments, the digital PCR assay is a multiplex digital PCR assay consisting of two or more PCR assays in a single digital PCR reaction. In some embodiments, the first single-plex digital PCR assay has a single copy of the recipient-specific target in the haploid recipient genome, and the second single-plex digital PCR assay has a single copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the second single-plex digital PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the multiplex digital PCR assay has at least one or two single copies of the recipient-specific target in the haploid recipient genome, and at least one or more single copies or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, each PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome.
[0013] In another aspect, a method for treating transplant rejection of a transplant from a donor in a transplant recipient is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by digital PCR assay, wherein the amount of donor-derived cell-free nucleic acid is determined by reference to the amount of the analyzed sample, or by digital PCR quantitative determination of donor-specific nucleic acid and recipient-specific nucleic acid as the ratio of donor-derived cell-free nucleic acid to total donor-specific and recipient-specific nucleic acid; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) based on the amount of donor-derived cell-free nucleic acid, immunosuppressant therapy is administered to the transplant recipient. In some embodiments, the digital PCR assay comprises one or more single-plex digital PCR assays. In some embodiments, the digital PCR assay is a multiplex digital PCR assay consisting of two or more PCR assays in a single digital PCR reaction. In some embodiments, the first single-plex digital PCR assay has a single copy of the recipient-specific target in the haploid recipient genome, and the second single-plex digital PCR assay has a single copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the second single-plex digital PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the multiplex digital PCR assay has at least one or two single copies of the recipient-specific target in the haploid recipient genome, and at least one or more single copies or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, each PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome.
[0014] In another aspect, a method for adjusting immunosuppressive therapy in a recipient of a transplant from a donor is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by digital PCR assay, wherein the amount of donor-derived cell-free nucleic acid is determined by reference to the amount of the analyzed sample, or by digital PCR quantitative determination of donor-specific nucleic acid and recipient-specific nucleic acid as the ratio of donor-derived cell-free nucleic acid to total donor-specific and recipient-specific nucleic acid; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) based on the amount of donor-derived cell-free nucleic acid, immunosuppressive therapy applied to the transplant recipient is adjusted. In some embodiments, the digital PCR assay comprises one or more single-plex digital PCR assays. In some embodiments, the digital PCR assay is a multiplex digital PCR assay consisting of two or more PCR assays in a single digital PCR reaction. In some embodiments, the first single-plex digital PCR assay has a single copy of the recipient-specific target in the haploid recipient genome, and the second single-plex digital PCR assay has a single copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the second single-plex digital PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, the multiplex digital PCR assay has at least one or two single copies of the recipient-specific target in the haploid recipient genome, and at least one or more single copies or multiple copies of the donor-specific target in the haploid donor genome. In some embodiments, each PCR assay has a double copy or multiple copies of the donor-specific target in the haploid donor genome.
[0015] In some embodiments that may be combined with any of the foregoing aspects or embodiments, the method further comprises testing for the presence of an infectious agent. In some embodiments, the infectious agent is selected from a virus, a bacterium, a fungus, or a parasite. In some embodiments, the infectious agent is a virus selected from cytomegalovirus, Epstein-Barr virus, Anelloviridae, or BK virus. In some embodiments that may be combined with any of the foregoing aspects or embodiments, the method further comprises performing one or more gene expression profiling assays in the recipient. In some embodiments, the combined score is calculated based on the amount of donor-derived cell-free nucleic acid in the sample and the results of the gene expression profiling assay.
[0016] In another aspect, the present invention provides a kit for detecting and monitoring the transplant rejection status of a transplant from a donor in a transplant recipient, wherein the donor and the recipient belong to different species, the kit comprising one or more PCR reaction oligonucleotide primers and probe sets that hybridize with donor-specific or recipient-specific target sequences in the cell-free nucleic acid from the transplant recipient for digital PCR quantification of the donor-derived cell-free nucleic acid with reference to the sample amount analyzed or with reference to the total cell-free nucleic acid analyzed; and instructions for data analysis for determining the amount of donor-derived cell-free nucleic acid.
[0017] In some embodiments that may be combined with any of the preceding aspects or embodiments, the donor-derived cell-free nucleic acid is DNA. In some embodiments that may be combined with any of the preceding aspects or embodiments, the donor-derived cell-free nucleic acid is DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpin, DNA / RNA hybrid, RNA hairpin, or a combination thereof.
[0018] In some embodiments that may be combined with any of the preceding aspects or embodiments, the amount of donor-derived cell-free nucleic acid is adjusted with a correction factor that corrects for differences in genome length between the donor and recipient genomes. In some embodiments that may be combined with any of the preceding aspects or embodiments, the amount of donor-derived cell-free nucleic acid is adjusted with a correction factor that corrects for differences in cell-free nucleic acid fragment size between cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient.
[0019] In some embodiments that may be combined with any of the preceding aspects or embodiments, the amount of donor-derived cell-free nucleic acid is a ratio of donor-derived cell-free nucleic acid to total or recipient-derived cell-free nucleic acid. In some embodiments, the ratio is a ratio of donor-derived cell-free nucleic acid mass to total or recipient-derived cell-free nucleic acid mass. In some embodiments, the ratio is a ratio of donor-derived cell-free nucleic acid genomic copy equivalents to total or recipient-derived cell-free nucleic acid genomic copy equivalents.
[0020] In some embodiments that may be combined with any of the preceding aspects or embodiments, the amount of donor-derived cell-free nucleic acid is a percentage of donor-derived cell-free nucleic acid compared to the total cell-free nucleic acid. In some embodiments, the percentage is a percentage of donor-derived cell-free nucleic acid mass compared to the total cell-free nucleic acid mass. In some embodiments, the percentage is a percentage of donor-derived cell-free nucleic acid genomic copy equivalents compared to the total cell-free nucleic acid genomic copy equivalents.
[0021] In some embodiments that may be combined with any of the preceding aspects or embodiments, the transplant is a solid organ, tissue, or cell transplant. In some embodiments that may be combined with any of the preceding aspects or embodiments, the donor of the transplant is an animal. In some embodiments, the animal is a pig.
[0022] In some embodiments that may be combined with any of the preceding aspects or embodiments, the next generation sequencing assay is amplicon-based.In some embodiments that may be combined with any of the preceding aspects or embodiments, the next generation sequencing assay is non-amplicon-based.
[0023] In another aspect, a method for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, wherein the sample comprises a cell-free nucleic acid derived from the donor and a cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of donor-derived cell-free nucleic acid is determined as: (i) absolute copies of donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid; and c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected. In some embodiments, the PCR assay is a quantitative PCR (qPCR) assay, and the PCR quantification is a real-time PCR quantification. In some embodiments, the PCR assay is a digital PCR assay and the PCR quantification is an end-point PCR quantification. In some embodiments, the digital PCR assay includes: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or receptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific target is associated with a haploid donor genome, and the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes a first single-plex digital PCR assay and a second single-plex digital PCR assay, wherein: (a) the first single-plex digital PCR assay is directed to a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) the second single-plex digital PCR assay is directed to a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the second single-plex digital PCR assay is directed to a multi-copy donor-specific target. In some embodiments, the multiplex digital PCR assay is directed to: (a) at least one single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) at least one single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the multiplex digital PCR assay is directed to at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
[0024] In another aspect, a method for treating transplant rejection of a transplant from a donor in a transplant recipient is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, wherein the sample comprises a cell-free nucleic acid derived from the donor and a cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of donor-derived cell-free nucleic acid is determined as: (i) absolute copies of donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) immunosuppressant therapy is administered to the transplant recipient based on the amount of donor-derived cell-free nucleic acid. In some embodiments, the PCR assay is a quantitative PCR (qPCR) assay, and the PCR quantification is real-time PCR quantification. In some embodiments, the PCR assay is a digital PCR assay and the PCR quantification is an end-point PCR quantification. In some embodiments, the digital PCR assay includes: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or receptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific target is associated with a haploid donor genome, and the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes a first single-plex digital PCR assay and a second single-plex digital PCR assay, wherein: (a) the first single-plex digital PCR assay is directed to a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) the second single-plex digital PCR assay is directed to a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the second single-plex digital PCR assay is directed to a multi-copy donor-specific target. In some embodiments, the multiplex digital PCR assay is directed to: (a) at least one single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) at least one single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the multiplex digital PCR assay is directed to at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
[0025] In another aspect, a method for adjusting immunosuppressive therapy in a recipient of a transplant from a donor is provided herein, wherein the donor and the recipient belong to different species, the method comprising: a) providing a sample from a transplant recipient after transplantation, wherein the sample comprises a cell-free nucleic acid derived from the donor and a cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein the amount of donor-derived cell-free nucleic acid is determined as: (i) absolute copies of donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid; c) if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold, transplant rejection is detected; and d) based on the amount of donor-derived cell-free nucleic acid, immunosuppressive therapy applied to the transplant recipient is adjusted. In some embodiments, the PCR assay is a quantitative PCR (qPCR) assay, and the PCR quantification is a real-time PCR quantification. In some embodiments, the PCR assay is a digital PCR assay and the PCR quantification is an end-point PCR quantification. In some embodiments, the digital PCR assay includes: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or receptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific target is associated with a haploid donor genome, and the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay comprises a first single-plex digital PCR assay and a second single-plex digital PCR assay, wherein: (a) the first single-plex digital PCR assay is directed to a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) the second single-plex digital PCR assay is directed to a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the second single-plex digital PCR assay is directed to a multi-copy donor-specific target. In some embodiments, the multiplex digital PCR assay is directed to: (a) at least one single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) at least one single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.In some embodiments, the multiplex digital PCR assay is directed to at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is correlated with a haploid donor genome.
[0026] In some embodiments that may be combined with any of the foregoing aspects or embodiments, the method further comprises testing for the presence of an infectious agent. In some embodiments, the infectious agent is selected from the group consisting of viruses, bacteria, fungi, and parasites. In some embodiments, the infectious agent is a virus selected from the group consisting of cytomegalovirus, Epstein-Barr virus, Anelloviridae, and BK virus. In some embodiments that may be combined with any of the foregoing aspects or embodiments, the method further comprises performing one or more gene expression profiling assays in the recipient. In some embodiments, a combined score is calculated based on the amount of donor-derived cell-free nucleic acid in the sample and the results of the gene expression profiling assay.
[0027] In another aspect, a kit for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient is provided herein, wherein the donor and the recipient belong to different species, the kit comprising: (a) one or more PCR reaction oligonucleotide primers and probe sets, which hybridize with donor-specific or recipient-specific target sequences in the cell-free nucleic acid in the sample from the transplant recipient for PCR quantification of donor-derived cell-free nucleic acid, as the absolute copy of donor-derived cell-free nucleic acid in the sample, or as the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid in the sample; and (b) instructions for data analysis for determining the amount of donor-derived cell-free nucleic acid. In some embodiments, PCR quantification is qPCR quantification. In some embodiments, PCR quantification is digital PCR quantification.
[0028] In some embodiments that can be combined with any of the foregoing aspects or embodiments, the cell-free nucleic acid of donor origin and / or the cell-free nucleic acid of recipient origin is DNA. In some embodiments that can be combined with any of the foregoing aspects or embodiments, the cell-free nucleic acid of donor origin and / or the cell-free nucleic acid of recipient origin is DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpin, DNA / RNA hybrid, RNA hairpin, or a combination thereof. In some embodiments that can be combined with any of the foregoing aspects or embodiments, the amount of the cell-free nucleic acid of donor origin is adjusted with a correction factor that corrects the difference in genome length between the donor and recipient genomes. In some embodiments that can be combined with any of the foregoing aspects or embodiments, the amount of the cell-free nucleic acid of donor origin is adjusted with a correction factor that corrects the difference in cell-free nucleic acid fragment size between the cell-free nucleic acid derived from the donor and the cell-free nucleic acid derived from the recipient. In some embodiments that can be combined with any of the foregoing aspects or embodiments, the amount of the cell-free nucleic acid of donor origin is the ratio of the cell-free nucleic acid of donor origin to the total or cell-free nucleic acid of the recipient. In some embodiments that may be combined with any of the preceding aspects or embodiments, the amount of donor-derived cell-free nucleic acid is the percentage of donor-derived cell-free nucleic acid compared to total cell-free nucleic acid. In some embodiments that may be combined with any of the preceding aspects or embodiments, the transplant is a solid organ, tissue, or cell transplant. In some embodiments that may be combined with any of the preceding aspects or embodiments, the donor of the transplant is an animal. In some embodiments, the animal is a pig.
[0029] In another aspect, the present invention provides a method for analyzing a biological sample from a transplant recipient receiving a solid organ transplant from a donor, wherein the donor and the recipient belong to different species, the method comprising: a) isolating cell-free nucleic acid from a biological sample from a transplant recipient, wherein the cell-free nucleic acid includes cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) generating amplicons by amplifying target regions of the cell-free nucleic acid, wherein the target regions include one or more target regions comprising donor-specific nucleotide sequences and / or one or more target regions comprising recipient-specific nucleotide sequences; c) generating sequence reads from the generated amplicons by sequencing the amplicons, wherein the generated sequence reads include one or more sequence reads corresponding to donor-specific genomic sequences and / or one or more sequence reads corresponding to recipient-specific genomic sequences, and optionally mapping the generated sequence reads to at least the donor-specific genomic sequence, optionally wherein the difference in genome size between the donor and the recipient is taken into account; and c) quantifying the amount of cell-free nucleic acid from the sequence reads generated in the sample. In some embodiments, the amount of cell-free nucleic acid is the amount of transplant donor-derived cell-free nucleic acid in the sample. In some embodiments, the amount of cell-free nucleic acid is the amount of total cell-free nucleic acid in the sample. In some embodiments, the method further comprises adding one or more quantitative spike nucleic acid controls to the sample, and generating sequence reads corresponding to one or more spike nucleic acid controls by sequencing the one or more spike nucleic acid controls, wherein the sequence reads corresponding to the spike controls are used to determine the absolute amount of total cell-free nucleic acid in the sample. In some embodiments, the method further comprises adding one or more quantitative spike nucleic acid controls to the sample, and generating sequence reads corresponding to one or more spike nucleic acid controls by sequencing the one or more spike nucleic acid controls, wherein the sequence reads from the spike controls are used to determine the absolute amount of cell-free nucleic acid of transplant donor origin in the sample. In some embodiments, one or more quantitative spike nucleic acid controls are added before step a). In some embodiments, one or more quantitative spike nucleic acid controls are added after step a). In some embodiments, one or more quantitative spike nucleic acid controls are added before and after step a). In some embodiments, the method further comprises using a correction factor to correct the difference in genome length between the donor genome and the recipient genome to account for the difference in genome size between the donor and the recipient.
[0030] In another aspect, the present invention provides a method for analyzing a biological sample from a transplant recipient receiving a solid organ transplant from a donor, wherein the donor and the recipient belong to different species, the method comprising: isolating cell-free nucleic acid from the biological sample from the recipient, wherein the cell-free nucleic acid includes cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; determining the amount of donor-derived cell-free nucleic acid in the sample by digital PCR assay, wherein the digital PCR assay includes: (i) at least one digital PCR assay for one or more single-copy or multi-copy donor-specific targets, or (ii) at least one digital PCR assay for one or more single-copy or multi-copy recipient-specific targets and one or more single-copy or multi-copy donor-specific targets, wherein the copy number of the donor-specific target is greater than the copy number of the recipient-specific target; Haploid donor genome is associated, and the copy number of the acceptor-specific target is associated with the haploid acceptor genome, and wherein by digital PCR quantification of the donor-specific nucleic acid and the acceptor-specific nucleic acid, the amount of the donor-derived cell-free nucleic acid is determined as: (i) the absolute copies of the donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of the donor-derived cell-free nucleic acid to the total donor-derived and acceptor-derived cell-free nucleic acid; in some embodiments, the digital PCR assay comprises (a) a first digital PCR assay for a single copy or multiple copies of the acceptor-specific target, wherein the copy number of the acceptor-specific target is associated with the haploid acceptor genome, and (b) a second digital PCR assay for a single copy or multiple copies of the donor-specific target, wherein the copy number of the donor-specific target is associated with the haploid donor genome. In some embodiments, the second digital PCR assay is for multiple copies of the donor-specific target. In some embodiments, digital PCR is measured for (a) at least one single copy or multiple copies of receptor-specific targets, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome; and (b) at least one single copy or multiple copies of donor-specific targets, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, digital PCR is measured for multiple copies of donor-specific targets, wherein the copy number of the donor-specific target is associated with a haploid donor genome. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1A to Figure 1B The accuracy and linearity of the digital PCR (dPCR) assay are shown to determine the percentage of porcine DNA in a sample containing a mixture of porcine and human DNA. In a control sample containing known percentages of control porcine and human genomic DNA, a double copy porcine-specific target ("Pig Assay A", see Table 2) and a single copy human-specific target ("Human Assay A", see Table 2) were used to generate a single-plex dPCR assay. Figure 1AThe results are shown. The x-axis shows the known percentage of porcine DNA in each sample (i.e., "Expected Porcine DNA %"), and the y-axis shows the percentage of porcine DNA as measured using the dPCR assay ("Measured Porcine DNA %"). Each point in the graph represents a sample, and the fitted line on the graph and the corresponding formula show the linearity of the expected and measured results. Figure 1B The results shown in were generated using a multiplex dPCR assay that included two single copy porcine assays ("Pig Assay B" and "Pig Assay C", see Table 2) and one single copy human assay ("Human Assay B", see Table 2).
[0032] Figure 2 A longitudinal analysis of the percentage of cfDNA derived from porcine donors (% dd-cfDNA) and copies per ml of plasma (cp / ml) in cfDNA samples from human transplant recipients of porcine heart transplants is provided, using single-plex dPCR ("Human Assay A" and "Porcine Assay A", see Table 2) to detect single-copy human-specific targets and double-copy porcine-specific targets (two porcine copies per haploid genome) as assessed. The percentage and cp / ml (y-axis) of cfDNA derived from porcine donors were determined in cfDNA samples obtained from human organ transplant recipients at several days after transplantation (i.e., days 6, 13, 19, 25, 33, 46, 55, and 60 after organ transplantation), as shown on the x-axis.
[0033] Figure 3 A longitudinal analysis of the percentage of cfDNA of pig origin in cfDNA samples of human recipients of porcine heart transplants evaluated using shotgun next generation sequencing (NGS) is provided. As described in Example 1 and Table 3 herein, NGS results were analyzed according to filtering models M1-M7. As shown on the x-axis, the percentage of cfDNA of pig donor origin was determined in cfDNA samples obtained from human organ transplant recipients several days after transplantation (i.e., 6, 13, 19, 25, 33, 46, 55, and 60 days after organ transplantation) (y-axis).
[0034] Figure 4 Comparison of the estimated percentage of cfDNA from porcine donors in samples from human recipients of porcine heart transplants as measured by singleplex dPCR ("Human Assay A" and "Porcine Assay A", see Table 2) or shotgun NGS is shown. As shown on the x-axis, the percentage of cfDNA from porcine donors was determined in cfDNA samples obtained from human organ transplant recipients several days after transplantation (i.e., days 6, 13, 19, 25, 33, 46, 55, and 60 after organ transplantation) (y-axis). As described in Example 1 and Table 3 herein, the NGS results were analyzed according to filter model M7.
[0035] Figure 5Comparison of the percentage of cfDNA derived from pig donors in samples from human recipients of pig heart transplants as measured by singleplex dPCR ("Human Assay A" and "Pig Assay A", see Table 2), multiplex dPCR ("Human Assay B", "Pig Assay B" and "Pig Assay C", see Table 2) and shotgun NGS is shown. As shown on the x-axis, the percentage of cfDNA derived from pig donors was determined in cfDNA samples obtained from human organ transplant recipients several days after transplantation (i.e., days 33, 46, 49 and 60 after organ transplantation) (y-axis). As described in Example 1 and Table 3 herein, the NGS results were analyzed according to filter model M7.
[0036] Fig. 6A and Figure 6B Comparison of the percentage of porcine donor-derived cfDNA (%xcfDNA) in samples from human death model recipients of porcine heart transplants (Recipient 1 and Recipient 2) as measured by multiplex dPCR ("Human Assay C" and "Porcine Assay D", see Table 2) or shotgun NGS is shown. The percentage of porcine donor-derived cfDNA (y-axis) was determined in cfDNA samples obtained from human death model recipients after transplantation, as shown on the x-axis (i.e., for Recipient 1, 30, 48, 72 hours after organ transplantation, Fig. 6A , and for recipient 2, at 0, 12, 24, 60, and 66 hours after organ transplantation, Figure 6B ). As described in Example 1 and Table 3 herein, the NGS results were analyzed according to filter model M7. Figure 6C and Fig.6D Figure 2 shows the expression of 1 (20 μg / ml) from a human death model recipient after transplantation as measured by multiplex dPCR ("Human Assay C" and "Porcine Assay D", see Table 2). Figure 6C ) and receptor 2 ( Fig.6D ) comparison of pig genome copies per mL sample. DETAILED DESCRIPTION
[0037] The following description is presented to enable a person skilled in the art to make and use various embodiments. Descriptions of specific devices, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be apparent to one of ordinary skill in the art, and the general principles defined herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Therefore, the various embodiments are not intended to be limited to the examples described herein, but should be given a scope consistent with the claims.
[0038] Overview
[0039] The present disclosure describes a sensitive and non-invasive method and kit for detecting, predicting, diagnosing and / or monitoring the health status of a transplant and for detecting, predicting and / or monitoring the transplant rejection status in a recipient of an organ, cell or tissue transplant from a donor, wherein the donor and the recipient belong to different species. Such methods and kits are based on the detection and quantification of donor-specific nucleic acids (such as DNA or RNA) in body fluids after transplantation, and body fluids include but are not limited to blood, serum, plasma or urine.
[0040] Transplanting organs, cells or tissues from donors to recipients triggers an immune response from the recipient's immune system, which may lead to acute and / or chronic transplant rejection. Without wishing to be bound by theory, it is believed that transplant rejection is associated with cell death from organs, tissues or cell transplants, which results in donor-derived nucleic acids (such as donor-derived cell-free DNA (dd-cfDNA)) being released from dying, no longer complete donor cells into the recipient's bloodstream and other body fluids. Therefore, the method disclosed herein relates to analyzing the cell-free DNA (cfDNA) in the sample of the recipient of the organ, cell or tissue transplant from the donor to diagnose the state of the transplant based on the amount of dd-cfDNA, wherein the donor and the recipient belong to different species. As disclosed herein, methods based on nucleic acid sequencing (e.g., high-throughput sequencing and / or next-generation sequencing methods) and methods based on PCR for quantitative nucleic acids (e.g., quantitative PCR [qPCR] and digital PCR [dPCR]) can be used to analyze the cfDNA in the sample obtained from the transplant recipient. See Examples 1 and 2 herein. Advantageously, the method based on nucleic acid sequencing of the present disclosure provides enhanced accuracy in the estimation of the amount of dd-cfDNA by taking into account the genome size difference between the donor and the recipient.See Examples 1 and 2 herein.Similarly, the method based on nucleic acid PCR of the present disclosure (e.g., a method based on dPCR), for example, by detecting a donor-specific target present in multiple copies in the haploid genome of the donor, provides enhanced sensitivity and accuracy in estimating the rare amount of dd-cfDNA.Therefore, as demonstrated herein, the method of the present disclosure allows, for example, by repeatedly and over an extended period of time, monitoring the amount of dd-cfDNA in the body fluid (e.g., blood) from the transplant recipient to the state of the organ, cell or tissue transplant in the transplant recipient to be sensitively, accurately and non-invasively monitored.See, for example, Examples 2 and 3 herein.
[0041] definition
[0042] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0043] The term "or" is used herein to mean, and is used interchangeably with, the term "and / or" unless the context clearly indicates otherwise.
[0044] As used herein, the term "sample" refers to any sample obtained from a transplant recipient, such as whole blood, plasma, serum, lymph, peripheral blood mononuclear cells, buccal swab, saliva, urine, lung lavage fluid, or tissue from a biopsy.
[0045] As used herein, the term "transplant" refers to a transplant of any cell, tissue or organ from a donor to a recipient, including combinations thereof. The term "transplant" with respect to a tissue or organ may refer to the entire tissue or organ (e.g., an entire liver) or a portion thereof.
[0046] As used herein, the term "nucleic acid" refers to linear, circular or branched, single-stranded or double-stranded RNA or DNA, or a hybrid thereof. The term also encompasses RNA / DNA hybrids. In some cases, nucleic acid refers to DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpins, DNA / RNA hybrids, RNA hairpins, and any of their fragments and combinations.
[0047] As used herein, the term "cell-free nucleic acid" refers to a nucleic acid present outside a cell. In some cases, the cell-free nucleic acid is a nucleic acid present outside a cell and present in the body fluids (e.g., blood, plasma, serum, urine, etc.) of a transplant recipient. In some embodiments, the cell-free nucleic acid refers to any DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpin, DNA / RNA hybrid, RNA hairpin, and fragments and combinations thereof present outside a cell. The term also includes organ-specific or tissue-specific RNA transcripts.
[0048] As used herein, the term "providing a sample" refers to providing a sample, for example, for use in the method of the present disclosure. In some cases, providing a sample includes performing a process for obtaining a sample (e.g., performing a physical method). In some cases, the sample is provided by the parties or entities performing the method of the present disclosure. In other cases, the sample is provided by an entity or party other than the parties or entities performing the method of the present disclosure. Therefore, in some cases, the method of the present disclosure includes receiving a sample from another party or source (e.g., a third party that obtains the sample).
[0049] As used herein, the term "generating sequence reads" refers to performing a process of obtaining sequence reads, such as for use in the methods of the present disclosure. For example, generating sequence reads may involve performing a sequencing method (e.g., a next generation sequencing (NGS) method or a high throughput sequencing (HTS) method). Such sequencing methods may involve whole genome sequencing or targeted sequencing, and nucleic acids may be sequenced, including but not limited to genomic DNA, mitochondrial DNA, cDNA obtained from RNA transcripts, or RNA. In some embodiments, at least 500, at least 1000, at least 5000, at least 10000, at least 20000, at least 50000, at least 100000 or more sequence reads may be generated. Each sequence read may include at least 20, at least 50, at least 75, at least 100, at least 150 or more bases per read. Sequence reads may be generated by parties or entities performing the methods of the present disclosure. In other cases, sequence reads may be generated by an entity or party other than parties or entities performing the methods of the present disclosure. Thus, in some cases, the methods of the present disclosure include receiving information or knowledge of sequence reads, or receiving sequence reads, from another party or source (e.g., a third party laboratory that directly generated or acquired the sequence reads).
[0050] As used herein, the term "target sequence" refers to a region of a nucleic acid comprising a sequence of interest. As used herein, the term "target" may comprise one or more target sequences.
[0051] All methods described herein may be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided with respect to certain embodiments herein is intended only to illustrate these embodiments and does not limit the scope of the otherwise claimed embodiments. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the embodiments.
[0052] I. Methods of the Disclosure
[0053] Certain aspects of the present disclosure relate to methods for detecting, predicting, diagnosing and / or monitoring the state of transplant rejection of an organ, tissue or cell transplant from a donor in a transplant recipient; methods for treating transplant rejection of an organ, tissue or cell transplant from a donor in a transplant recipient; and methods for adjusting immunosuppressive therapy in a transplant recipient of an organ, tissue or cell transplant from a donor. Other aspects of the present disclosure relate to methods for analyzing biological samples from transplant recipients, for example, to quantify cell-free nucleic acids, such as cell-free nucleic acids of donor origin, cell-free nucleic acids of recipient origin and / or total cell-free nucleic acids (e.g., using sequencing or PCR-based methods). In some embodiments, an organ, tissue or cell transplant according to the present disclosure is a cross-species transplant (i.e., a xenogeneic or allogeneic transplant), in which the organ, tissue or cell transplant donor is a species different from the transplant recipient. Thus, in some embodiments, the methods disclosed herein include detecting, predicting, diagnosing and / or monitoring the transplant rejection state of a cross-species, xenogeneic or allogeneic organ, tissue or cell transplant in a transplant recipient; treating the transplant rejection of a cross-species, xenogeneic or allogeneic organ, tissue or cell transplant in a transplant recipient; and adjusting immunosuppressive therapy in a transplant recipient of a cross-species or xenogeneic organ, tissue or cell transplant.
[0054] In some embodiments, the method of the present disclosure includes providing a sample of a recipient of an organ, tissue or cell transplant from a donor after transplantation, wherein the sample from the transplant recipient contains a cell-free nucleic acid (e.g., cfDNA and / or cfRNA) derived from the donor and a cell-free nucleic acid (e.g., cfDNA and / or cfRNA) derived from the recipient; Determine the amount of cell-free nucleic acid of the donor source in the cell-free nucleic acid from the sample; And detect transplant rejection based on the amount of cell-free nucleic acid of the determined donor source. In some embodiments, the method includes detecting transplant rejection if the amount of cell-free nucleic acid of the determined donor source exceeds a predetermined threshold. In some embodiments, the method of the present disclosure includes administering immunosuppressant therapy to the transplant recipient based at least in part on the detection of transplant rejection (e.g., based on the amount of cell-free nucleic acid of the determined donor source). In some embodiments, the method of the present disclosure includes adjusting the immunosuppressant therapy of the transplant recipient based at least in part on the detection of transplant rejection (e.g., based on the amount of cell-free nucleic acid of the determined donor source).
[0055] In some embodiments, the amount of donor-derived cell-free nucleic acid is determined using a sequencing-based method, such as high-throughput sequencing (HTS) and / or next-generation sequencing (NGS), as described in more detail below. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined using a nucleic acid PCR-based quantitative method, such as quantitative PCR (qPCR) or digital PCR (dPCR), as described in more detail below.
[0056] A. Quantification of Cell-free Nucleic Acids
[0057] Certain aspects of the present disclosure relate to methods for determining the amount of donor-derived cell-free nucleic acid in a sample from a transplant recipient using sequencing-based methods or nucleic acid PCR-based quantification methods, as described in more detail below.
[0058] Other aspects of the present disclosure relate to methods for quantifying cell-free nucleic acids in a biological sample from a transplant recipient, such as recipient-derived cell-free nucleic acids, donor-derived cell-free nucleic acids, and / or total cell-free nucleic acids.
[0059] Sequencing-based methods
[0060] In some embodiments, the methods of the present disclosure include determining the amount of cell-free nucleic acid (e.g., recipient-derived cell-free nucleic acid, donor-derived cell-free nucleic acid, and / or total cell-free nucleic acid) in the cell-free nucleic acid in a sample from a transplant recipient using a nucleic acid sequencing-based method.
[0061] Various methods and schemes for nucleic acid sequencing and analysis well known in the art can be used in the method of the present disclosure.For example, DNA sequencing can be completed using high-throughput sequencing (HTS) technology, whole genome sequencing, shotgun sequencing, whole exome sequencing, targeted sequencing, Sanger sequencing, massively parallel sequencing technology or next generation sequencing (NGS). The example of next generation and high-throughput sequencing includes, for example, massively parallel signature sequencing, polymerase clone sequencing, 454 pyrophosphate sequencing, Illumina (Solexa) sequencing using HiSeq, MiSeq and other Illumina platforms, SOLiD sequencing, ion semiconductor sequencing (IonTorrent), nanopore sequencing (see, for example, website: anoporetech.com / applications / short-fragment-mode), DNA nanoball sequencing, heliscope single molecule sequencing, single molecule real-time (SMRT) sequencing, Digital Analysis of Selected Regions (DANSR TM) See, for example, Stein RA (2008). “Next-Generation Sequencing Update”. Genetic Engineering & Biotechnology News 28(15); Quail et al., (2012). “A tale of three next generation sequencing platforms: comparison of Ion torrent, pacific biosciences and illumina MiSeq sequencers”. BMC Genomics 13(1):341; Liu et al., (2012). “Comparison of Next-Generation Sequencing Systems”. Journal of Biomedicine and Biotechnology 2012:1-11; Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption / ionization time-of-flight mass spectrometry Methods Mol Biol. 2009;578:307-43; Chu et al., A novel approach toward the challenge of accurately quantifying fetal DNA in maternal plasma. Prenat Diagn 2010;30:1226-9; and Suzuki et al., Characterization of circulating DNA in healthy human plasma. Clinicachimica acta; international journal of clinical chemistry 2008;387:55-8.
[0062] In some embodiments, the method of the present disclosure includes generating sequence reads corresponding to one or more donor-specific genomic sequences and / or receptor-specific genomic sequences in the cell-free nucleic acid of the sample obtained from the transplant recipient. In some embodiments, the sequence reads are generated using any suitable sequencing method known in the art, such as high-throughput sequencing (HTS) technology or next-generation sequencing (NGS), for example as described above. In some embodiments, NGS shotgun sequencing is used, for example, using MiSeq or NextSeq sequencing platforms from Illumina to generate sequence reads. In some embodiments, paired end sequencing is used to generate sequence reads. In some embodiments, amplicon-based NGS is used to generate sequence reads, wherein PCR is used, for example, to amplify the target region of the genome before sequencing. In some embodiments, non-amplicon-based NGS is used, for example, hybrid capture NGS is used to generate sequence reads. In some embodiments, for donor and recipient genomes, sequence reads are grouped into regions of selected sizes of the same size. In some embodiments, the method includes mapping sequence reads to donor and / or recipient-specific genomic sequences. In some embodiments, mapping includes aligning sequence reads with reference sequences. Any suitable method known in the art can be used, such as using a Burrows-Wheeler aligner (BWA) for alignment or mapping. In some embodiments, the sequence reads are aligned with a minimum alignment score cutoff of about 90%, an allowed gap percentage of about 5%, and / or a non-split alignment. In some embodiments, the reference sequence comprises a reference genome corresponding to a donor and / or a reference genome corresponding to a recipient. In some embodiments, the reference sequence is a combined reference sequence comprising a reference genome corresponding to a donor and a reference genome corresponding to a recipient. In some embodiments, the method includes excluding one or more sequence reads that are multiple matches with the reference sequence from the aligned or mapped sequence reads. In some embodiments, the method includes excluding one or more sequence reads with a missing mate, a translocated sequence read, and a sequence read with an incorrect orientation from the aligned or mapped sequence reads. In some embodiments, the method includes excluding one or more sequence reads with an alignment score less than 95% or less than 98% from the aligned or mapped sequence reads. In some embodiments, the method includes excluding one or more partially aligned sequence reads or soft spliced sequence reads from the aligned or mapped sequence reads. In some embodiments, the method includes excluding one or more partially aligned sequence reads or hard and soft spliced sequence reads from the aligned or mapped sequence reads, or wherein the alignment to MAPQ is less than 10.
[0063] In some embodiments, the amount of donor-derived cell-free nucleic acid in the cell-free nucleic acid in a sample from a transplant recipient is determined based on the percentage of sequence reads that align to the donor genome as the fraction of sequence reads that align to both the donor and recipient genomes.
[0064] In some embodiments, the methods of the present disclosure include accounting for differences in genome size between the recipient and the donor to determine the amount of donor-derived cell-free nucleic acid in the sample.
[0065] In some embodiments, the genome size difference between the recipient and the donor is taken into account based on the sequencing coverage of the donor and recipient genomes in the generated sequence reads. In some embodiments, the genome size difference between the recipient and the donor is taken into account based on the average coverage of one or more regions of the selected size across the donor and recipient genomes in the generated sequence reads. In some embodiments of such embodiments, the amount of cell-free nucleic acid from the donor source is determined as the average coverage percentage of one or more regions of the selected size across the donor and recipient genomes. In some embodiments, one or more regions of the selected size are large enough to have sufficient coverage. In some embodiments, the background noise is low enough to distinguish between the donor and recipient genomes. In some cases, the amount of cell-free nucleic acid from the donor source is determined as m d / (m d +m r )×100, where m d is the median of the average coverage across one or more regions of the donor genome of a selected size, and m r It is the median of the average coverage of one or more regions of the recipient genome across the selected size. In some embodiments, the region of the selected size of the donor and recipient genomes comprises at most 1 megabase (Mb), between about 1Mb and about 10Mb, at most 10Mb, between about 10Mb and about 100Mb, or at most any one of 100Mb. In some embodiments, the region of the selected size of the donor and recipient genomes comprises at most 1M bases, at most 10M bases, or at most 100M bases.
[0066] In some embodiments, a correction factor is used to account for differences in genome size between the recipient and the donor. For example, for a donor genome that is smaller than the recipient genome, a correction factor can be obtained by multiplying the fraction of sequence reads mapped to the donor-specific genomic sequence by the ratio of the donor genome size to the recipient genome size.
[0067] The size of the cell-free nucleic acid fragments of donor origin and the cell-free nucleic acid fragments of receptor origin can be different, see, for example, Example 2 and Table 4 herein, which shows that compared with the cell-free DNA fragments from human transplant recipients, differences are observed in the average fragment size of the cell-free DNA fragments of pig donor origin. Such differences in fragment size between the cell-free nucleic acid of donor origin and the cell-free nucleic acid of receptor origin can lead to an overestimation or underestimation of the amount of the cell-free nucleic acid of donor origin. Therefore, in some embodiments, the method includes, for example, using a correction factor to account for the possible overestimation or underestimation of the amount of the cell-free nucleic acid of donor origin caused by the difference in fragment size of the cell-free nucleic acid of donor origin and the cell-free nucleic acid of receptor origin. For example, the correction factor can be determined by comparing the fragment size in artificial and computer simulated samples. In addition, the difference in fragment size between the cell-free nucleic acid of donor origin and the cell-free nucleic acid of receptor origin can also lead to an overestimation or underestimation of the sequencing coverage of the donor and receptor genomes in the generated sequence reads. For example, smaller nucleic acid fragments can obtain greater coverage than larger nucleic acid fragments. Thus, in some embodiments, the method includes accounting for possible overestimation or underestimation of sequencing coverage of the donor and recipient genomes due to differences in fragment size between the donor-derived cell-free nucleic acid and the recipient-derived cell-free nucleic acid, for example, using a correction factor. For example, the correction factor can be determined by multiplying the coverage score (e.g., the average coverage score of a region of a selected size across the donor and recipient genomes) by the ratio of the average donor nucleic acid fragment size to the average recipient nucleic acid fragment size.
[0068] In some embodiments, absolute quantification of the amount of donor-derived cell-free nucleic acid in the cell-free nucleic acid in the sample from the transplant recipient can be accomplished by including a control nucleic acid (e.g., a quantitative spike nucleic acid control) of known concentration or amount in the sample from the transplant recipient or in the cell-free nucleic acid from the transplant recipient prior to generating sequence reads. The absolute amount of donor-derived cell-free nucleic acid is then determined based on the sequence reads corresponding to the control nucleic acid and corresponding to the donor-derived cell-free nucleic acid.
[0069] Where there are multiple cell-free nucleic acid samples from transplant recipients to be sequenced, such as when multiple samples are taken from transplant recipients over time or when samples are taken from various transplant recipients, each sample can be sequenced individually or the multiple samples can be sequenced together using multiplex sequencing.
[0070] Nucleic acid PCR-based quantitative methods
[0071] In some embodiments, the methods of the present disclosure include determining the amount of cell-free nucleic acid (e.g., recipient-derived cell-free nucleic acid, donor-derived cell-free nucleic acid, and / or total cell-free nucleic acid) in cell-free nucleic acid from a sample obtained from a transplant recipient using a nucleic acid PCR quantification method.
[0072] Various methods and protocols for nucleic acid quantification are well known in the art, such as quantitative nucleic acid amplification methods, including quantitative polymerase chain reaction (qPCR), digital PCR (dPCR), and real-time dPCR.
[0073] qPCR or real-time quantitative PCR refers to a method of simultaneously amplifying and quantifying a target nucleic acid using PCR. As known in the art, quantification of the accumulated amplified nucleic acid in a qPCR reaction is performed in real time after each amplification cycle. Absolute quantification can be performed using a standard curve, and quantification can be performed using the following: detectably labeled probes, primers, or dyes, such as intercalating dyes that bind to double-stranded DNA products, such as YO-PRO-I, SYBR Green, etc. (see, e.g., Ishiguro et al., Anal. Biochem., 229:207-213 (1995); Tseng et al., Anal. Biochem., 245:207-212 (1997); Morrison et al., Biotechniques, 24:954-962 (1998)); primers having a hairpin structure with a fluorescent molecule that remains near a fluorescent quencher until forced apart by primer extension (see, e.g., Whitecombe et al., Nature Biotechnology, 17:804-807 (1999; "AMPLIFLUOR or sequence-specific probes, which typically contain fluorescent molecules that are in close proximity to a fluorescent quencher until the oligonucleotide moiety to which they are attached specifically binds to the amplification product (see, e.g., Gelfand et al., U.S. Pat. No. 5,210,015 (TAQMAN); Nazarenko et al., Nucleic Acids Research, 25:2516-2521 (1997) (scorpion probes); Tyagi et al., Nature Biotechnology, 16:49-53 (1998) (molecular beacons). Other suitable dyes, primers, or probes that can be used include dual hybridization probes, eclipse probes, LUX PCR primers, and QZyme PCR primers. Such dyes, primers or probes can be used in conjunction with qPCR as described herein, or they can be used to measure the total amount of reaction product when the reaction is complete. In some embodiments, the detectably labeled probe, primer or dye is fluorescently labeled, for example, using one or more of FAM, HEX, ATTO550, ROX, Cy5, Cy5.5 or any other suitable dye.
[0074] Digital PCR or dPCR refers to a method allowing absolute quantification of target nucleic acid. As known in the art, dPCR is carried out by dividing the PCR reaction into multiple partitions so that each partition contains one, several or does not contain a target sequence. After the PCR reaction, that is, at the end of the PCR reaction, the total number of positive and partitions is amplified for quantitative target sequences using Poisson statistics. Positive partitions can be identified using detectably labeled probes, primers or dyes, for example, as described above for qPCR. In some embodiments, detectably labeled probes, primers or dyes are fluorescently labeled, for example, using one or more of FAM, HEX, ATTO 550, ROX, Cy5, Cy5.5 or any other suitable dye. For a description of dPCR methods, see, e.g., Hindson et al., (2011) Anal. Chem. 83(22):8604-8610; Pohl and Shih (2004) Expert Rev. Mol. Diagn. 4(1):41-47; Pekin et al., (2011) Lab Chip 11(13):2156-2166; Pinheiro et al., (2012) Anal. Chem. 84(2):1003-1011; Day et al. (2013) Methods 59(1):101-107; and Quan et al., Sensors (Basel). 2018 Apr;18(4):1271. Multiple partitions can be generated using any suitable method known in the art, such as by partitioning the PCR reaction into microwells, chambers, or droplets. In instances where multiple partitions are generated by partitioning the PCR reaction into droplets, the dPCR method may be referred to as droplet digital PCR, e.g., as described in ddPCR from BioRad. TM ) or Stilla (e.g., Crystal digital PCR TM ) available.
[0075] In some embodiments, the methods of the present disclosure comprise determining the amount of donor-derived cell-free nucleic acid in a sample using a digital PCR assay.
[0076] In some embodiments, dPCR determination includes one or more single dPCR determinations. In some embodiments in such embodiments, single dPCR determinations may include one or more receptor-specific single dPCR determinations, and / or one or more donor-specific single dPCR determinations. In some embodiments, receptor-specific single PCR determinations and donor-specific single PCR determinations each have a single copy target per haploid genome. In some embodiments, receptor-specific single dPCR determinations and / or donor-specific single dPCR determinations in some or all of each haploid genome have multiple copies (e.g., double copies or more copies) of targets, which generate more target positive partitions for the same amount of sample input (e.g., for the same amount of sample inputs generate two or more times of target positive partitions) to increase the determination detection and quantitative sensitivity and precision. This is particularly useful in the case where the amount of donor-derived cell-free nucleic acid in the total cell-free nucleic acid from the sample is very little. In some embodiments, multi-copy target PCR determinations can target multiple members of a multigene family, such as actin, tubulin, rRNA gene families, or multiple members of a repetitive sequence, such as an Alu sequence, or multiple copies of the mitochondrial DNA of each diploid cell. In some embodiments, the dPCR assay includes at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome. In some embodiments, the digital PCR assay includes a first single-plex digital PCR assay and a second single-plex digital PCR assay, wherein: (a) the first single-plex digital PCR assay is for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) the second single-plex digital PCR assay is for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the second single-plex digital PCR assay is for a multi-copy donor-specific target. Quantification of cell-free nucleic acids determined by different dPCRs targeting different copy number targets can be normalized to genome copy quantification for analysis of relative quantification of donor-derived genome to total donor and recipient genomes, or absolute quantification of donor-derived genome copies per unit sample (e.g., copies per ml of plasma sample).
[0077] In some embodiments, dPCR assay is a multiplex dPCR assay comprising two or more PCR assays in a single dPCR reaction. In some such embodiments, multiplex dPCR assays may include at least one donor-specific PCR assay. In some embodiments, multiplex dPCR assays may include at least one donor-specific PCR assay and at least one receptor-specific PCR assay, for quantitatively determining the cell-free nucleic acid of a donor source relative to a receptor or total cell-free nucleic acid. In some embodiments, multiplex dPCR assays may include receptor-specific PCR assays and donor-specific PCR assays, each targeting at least one single copy target per haploid genome of a species. In some embodiments, multiplex dPCR assays may include receptor-specific PCR assays and donor-specific PCR assays, each targeting at least one multi-copy target per haploid genome to improve target detection and quantitative sensitivity with limited sample input. In some embodiments, multiplex dPCR assays may include at least one donor-specific PCR assay, which has at least one single copy or multi-copy target (e.g., double copy target or more copy target) corresponding to a haploid donor genome (i.e., each donor-specific PCR assay detects at least one single copy or multi-copy target corresponding to a donor), wherein the copy number of the target is related to the haploid genome of the donor. In some embodiments, the multiplex dPCR assay may include one or more (e.g., between one and five) donor-specific PCR assays having at least one single copy or multiple copy target (e.g., at least one double copy target or more copy target) corresponding to the donor genome (i.e., each donor-specific PCR assay detects at least one single copy or multiple copy target corresponding to the donor), wherein the copy number of the target is associated with the haploid genome of the donor. In some embodiments, the multiplex dPCR assay may include at least one receptor-specific PCR assay having at least one single copy or multiple copy target corresponding to the haploid receptor genome (i.e., each receptor-specific PCR assay detects at least one single copy or multiple copy target corresponding to the receptor), wherein the copy number of the target is associated with the haploid genome of the receptor. In some embodiments, the multiplex dPCR assay may include one or more (e.g., between one and five) receptor-specific PCR assays having at least one single copy or multiple copy target corresponding to the receptor genome (i.e., each receptor-specific PCR assay detects at least one single copy or multiple copy target corresponding to the receptor), wherein the copy number of the target is associated with the haploid genome of the receptor. In some embodiments, the digital PCR assay includes at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or acceptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific targets is associated with a haploid donor genome and the copy number of the acceptor-specific targets is associated with a haploid acceptor genome.In some embodiments, the multiplex digital PCR assay is directed to: (a) at least one single copy or multiple copies of a receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and (b) at least one single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the multiplex digital PCR assay is directed to at least one multiple copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
[0078] In some embodiments, the dPCR assay includes at least one digital PCR assay for one or more single-copy or multi-copy donor-specific targets. In some embodiments, the dPCR assay includes at least one digital PCR assay for one or more single-copy or multi-copy receptor-specific targets and one or more single-copy or multi-copy donor-specific targets. In some embodiments, the dPCR assay includes a first digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome, and a second digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the second digital PCR assay is directed to a multi-copy donor-specific target.
[0079] In some embodiments, the digital PCR assay is directed to at least one single copy or multiple copies of a receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome; and at least one single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome. In some embodiments, the digital PCR assay is directed to multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
[0080] In some embodiments, the single copy target corresponding to the recipient is present in the haploid genome of the recipient as a single copy, and is not present in the genome of the donor. In some embodiments, the single copy target corresponding to the donor is present in the haploid genome of the donor as a single copy, and is not present in the genome of the recipient. In some embodiments, the multi-copy target (e.g., double copy target or multi-copy target) corresponding to the donor is present in the haploid genome of the donor with multiple (e.g., two or more) copies, and is not present in the genome of the recipient. In some embodiments, the target corresponding to the donor and / or the target corresponding to the recipient is in the intron region of the donor or recipient genome. In some embodiments, the target corresponding to the donor and / or the target corresponding to the recipient is in the mitochondrial DNA of the donor or recipient genome. In some embodiments, the multi-copy (e.g., double copy target or multi-copy) target corresponding to the donor includes the sequence of a multi-gene family in the donor genome. Non-limiting examples of multi-gene families include rRNA, Hox, histone and tubulin gene families.
[0081] In some embodiments, each receptor-specific PCR assay comprises a primer pair that detects a receptor-specific target (e.g., a single copy or multiple copy target corresponding to a receptor), such as by directly amplifying the receptor-specific target during a PCR reaction. In some embodiments, each donor-specific PCR assay comprises a primer pair that detects a donor-specific target (e.g., a single copy or multiple copy target corresponding to a donor), such as by directly amplifying the donor-specific target during a PCR reaction. In some embodiments, the length of each primer in the primer pair is between about 5 and about 50, between about 10 and about 50, between about 15 and about 30, between about 15 and about 25, between about 18 and about 30, or between about 20 and about 30 bases, including any value within each of the ranges. In some embodiments, each primer in the primer pair has a melting temperature (T) of about 55°C, about 56°C, about 57°C, about 58°C, about 59°C, about 60°C, about 61°C, about 62°C, about 63°C, about 64°C, about 65°C, about 66°C, about 67°C, about 68°C, about 69°C, or about 70°C. m In some embodiments, each primer in the primer pair has a melting temperature (T m ).
[0082] As described above, the detection of donor-specific or receptor-specific positive partitions in dPCR assays can be performed using any suitable detection reagent, such as using DNA-binding fluorescent dyes (such as SYBR green or EvaGreen) or detectably labeled probes (e.g., fluorescently labeled probes). In the case of using detectably labeled probes to detect donor-specific or receptor-specific positive partitions, receptor-specific PCR or donor-specific PCR assays include detectably labeled probes suitable for detecting receptor-specific or donor-specific targets, respectively. In some embodiments of such embodiments, each receptor-specific PCR assay includes primer pairs for detecting receptor-specific targets (e.g., corresponding to single or multiple copies of a receptor), and detectably labeled probes hybridized with receptor-specific targets; and / or each donor-specific PCR assay includes primer pairs for detecting donor-specific targets (e.g., corresponding to single or multiple copies of a donor), and detectably labeled probes hybridized with donor-specific targets. In some embodiments, detectably labeled probes include oligonucleotides configured to hybridize with receptor-specific targets or with donor-specific targets, fluorescent tags, and quenchers. In some embodiments, the fluorescent label is at one end of the oligonucleotide, and the quencher is at the other end of the oligonucleotide. In some embodiments, the fluorescent label is any label or dye known in the art, including but not limited to FAM, HEX, ATTO 550, ROX, Cy5 and Cy5.5. In some embodiments, the quencher is any quencher known in the art, such as BHQ, IABkFQ, TAMRA. In some embodiments, the oligonucleotide comprises a sequence of bases between about 5 and about 50, between about 10 and about 50, between about 15 and about 30, between about 15 and about 25, or between about 20 and about 30 in length, including any value within each of the ranges. In some embodiments, the probe has a melting temperature (T) of any one of about 60°C, about 61°C, about 62°C, about 63°C, about 64°C, about 65°C, about 66°C, about 67°C, about 68°C, about 69°C or about 70°C. m In some embodiments, the probe has a melting temperature (T) between about 65°C and about 70°C. m ), including any value within that range.
[0083] In some embodiments, the dPCR assay comprises one or more single-plex PCR assays (e.g., an acceptor-specific PCR assay, and / or a donor-specific PCR assay), and each single-plex PCR assay comprises the use of a detection reagent having a unique dye or detectable label (e.g., a unique fluorescent dye or label). For example, in a dPCR assay comprising one or more single PCR assays (e.g., an acceptor-specific PCR assay, and / or a donor-specific PCR assay), the acceptor-specific PCR assay comprises a detection reagent having a first fluorescent label, and the donor-specific PCR assay comprises a detection reagent having a second fluorescent label different from the first fluorescent label. Thus, in one embodiment, the dPCR assay comprises a receptor-specific PCR assay comprising a primer pair for detecting a receptor-specific target (e.g., a single copy or multiple copies of a target corresponding to a receptor), and a detectably labeled probe that hybridizes to the receptor-specific target, wherein the detectably labeled probe is labeled with a first fluorescent label; and a donor-specific PCR assay comprising a primer pair for detecting a donor-specific target (e.g., a single copy or multiple copies of a target corresponding to a donor), and a detectably labeled probe that hybridizes to the donor-specific target, wherein the detectably labeled probe is labeled with a second fluorescent label different from the first fluorescent label.
[0084] In some embodiments, the dPCR assay is a multiplex dPCR assay, which comprises two or more PCR assays in a single dPCR reaction, such as at least one donor-specific PCR assay, for quantifying donor-derived cell-free nucleic acid as absolute copies of donor-derived cell-free nucleic acid in a sample, such as absolute donor (genomic) copies per mL of sample, such as copies per mL of plasma, or as donor (genomic) copies per DNA amount, such as copies per ng DNA. In some embodiments, the dPCR assay is a multiplex dPCR assay, which comprises two or more PCR assays in a single dPCR reaction, such as at least one donor-specific PCR assay, and one or more receptor-specific PCR assays for relative donor-derived cell-free nucleic acid quantification with respect to receptor-derived cell-free nucleic acid or total donor and receptor-derived cell-free nucleic acid in a reference sample, wherein a detection reagent comprising a unique dye or detectable label (e.g., a unique fluorescent dye or label) is used for each PCR assay in the multiplex dPCR reaction; or wherein at least two PCR assays in the multiplex dPCR reaction comprise a detection reagent containing the same dye or detectable label (e.g., the same fluorescent dye or label). Thus, in one embodiment, in a multiplex dPCR assay comprising at least one receptor-specific PCR assay and at least one donor-specific PCR assay in a single dPCR reaction, each PCR assay in the dPCR reaction may include a detection reagent having a unique fluorescent dye or label. For example, a multiplex dPCR assay may include at least one receptor-specific PCR assay with a single copy or multiple copies of a target corresponding to a receptor and at least one donor-specific PCR assay with a single copy or multiple copies (e.g., two copies or more copies) of a target corresponding to a donor, wherein each PCR assay in the dPCR reaction (i.e., each receptor-specific PCR assay and each donor-specific PCR assay) includes a detection reagent having a unique fluorescent dye or label. In another embodiment, in a multiplex dPCR assay comprising at least one receptor-specific PCR assay and at least one donor-specific PCR assay in a single dPCR reaction, at least two receptor-specific or donor-specific PCR assays in the dPCR reaction include detection reagents containing the same dye or detectable label (e.g., the same fluorescent dye or label). For example, a multiplex dPCR assay can include at least one acceptor-specific PCR assay having a single copy or multiple copies of a target corresponding to the acceptor and two or more donor-specific PCR assays having a single copy or multiple copies (e.g., two copies or more) of a target corresponding to a donor, wherein at least two of the donor-specific PCR assays in the dPCR reaction contain detection reagents having the same fluorescent dye or label.
[0085] The amount of donor-derived cell-free nucleic acid present in a cell-free nucleic acid sample from a transplant recipient (e.g., as determined according to the methods of the present disclosure) can be expressed in a variety of ways. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined as a percentage of the total cell-free nucleic acid in the sample. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined as an absolute copy of the donor-derived cell-free nucleic acid in the sample. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined as a ratio of donor-derived cell-free nucleic acid to total cell-free nucleic acid (e.g., total donor-derived cell-free nucleic acid and recipient-derived cell-free nucleic acid) in the sample. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined as a ratio of donor-derived cell-free nucleic acid to recipient-derived cell-free nucleic acid in the sample. In some embodiments, the amount of donor-derived cell-free nucleic acid is determined as a ratio or percentage compared to one or more reference nucleic acid molecules in the sample. For example, the amount of donor-derived cell-free nucleic acid can be determined as 10% of the total nucleic acid (or total DNA or RNA) molecules in the cell-free nucleic acid sample. Alternatively, the ratio of the amount of donor-derived cell-free nucleic acid to the total nucleic acid (or DNA or RNA) molecules in the cell-free DNA sample can be 1:10. In some embodiments, the amount of donor-derived cell-free nucleic acid can be determined as a concentration. For example, the amount of donor-derived cell-free nucleic acid in a cell-free nucleic acid sample can be determined as 1 μg / mL sample; 100 donor (genome) copies / mL sample; 10 donor (genome) copies / DNA amount, such as 10 donor (genome) copies / ng DNA, etc. The values described herein are merely exemplary to illustrate various ways of expressing the amount of donor-derived cell-free nucleic acid. The percentage of donor-derived cell-free nucleic acid in a cell-free nucleic acid sample from a transplant recipient can be extremely low. It should be noted that the amount of recipient-derived cell-free nucleic acid in a cell-free nucleic acid sample can also be expressed in the manner described for donor-derived cell-free nucleic acid. Additional methods for expressing the amount of nucleic acid of a given source, type or sequence in a cell-free nucleic acid sample are obvious to those skilled in the art.
[0086] In some embodiments, the amount of donor-derived cell-free nucleic acid is determined with reference to the amount of sample analyzed by dPCR assay. In some embodiments, the amount of donor-derived cell-free nucleic acid can be determined as the number of copies of the donor genome in the sample from the transplant recipient (e.g., per mL sample, or the number of copies of the donor genome per cell-free nucleic acid amount in the sample). In one embodiment, the amount of donor-derived cell-free nucleic acid can be determined as the number of copies of the donor genome per volume of the sample from the recipient, such as the number of copies of the donor genome per volume (e.g., mL) of the plasma from the recipient. In another embodiment, the amount of donor-derived cell-free nucleic acid can be determined as the number of copies of the donor genome per total cell-free nucleic acid amount in the sample from the recipient, such as the number of copies of the donor genome per ng of cell-free nucleic acid in the sample from the recipient. In one example, the copy number of the donor-specific target sequence molecule as determined by the dPCR assay (e.g., as the copy number of the donor DNA molecule per μL) is adjusted to the copy number of the donor-specific haploid genome in the dPCR assay (e.g., in a donor-specific PCR assay for a double-copy target corresponding to the donor haploid genome, the copy number of the donor target sequence as determined by the dPCR assay is divided by two copies / haploid genome). The copy number of the recipient target sequence molecule as determined by the dPCR assay can be adjusted as described above for the donor-specific target sequence. Next, based on the volume used for the dPCR assay, the volume of the cell-free nucleic acid from the sample (e.g., the volume of the cell-free nucleic acid extracted from the sample from the transplant recipient), and the volume of the sample from the transplant recipient (e.g., the volume of the transplant recipient's sample from which the cell-free nucleic acid was extracted), the copy number of the donor genome in the sample from the transplant recipient is determined (e.g., the copy number of the donor genome per mL of sample, or per amount of cell-free nucleic acid in the sample). Where two or more PCR assays in a dPCR reaction (eg, in a multiplex dPCR assay) comprise detection reagents having the same fluorescent dye or label, the method further comprises normalizing the number of PCR assays comprising detection reagents having the same fluorescent dye or label.In one example of a multiplex dPCR assay with two donor-specific single-copy target PCR assays in dPCR reactions containing detection reagents with the same fluorescent dye or label, the copy number of the donor-specific target sequence as determined by the dPCR assay (e.g., as the sum of the copy number of the donor-specific sequence per μL) is adjusted by (divided by) the number of donor-specific PCR assays in dPCR reactions containing detection reagents with the same fluorescent dye or label (e.g., in a dPCR assay with two donor-specific PCR assays containing detection reagents with the same fluorescent dye or label, the copy number of the donor genome per μL is obtained by dividing the measured total copies / μL by two), and adjusted to the copy number of each donor-specific target in the PCR assay (e.g., in a donor-specific PCR assay for a double-copy target corresponding to the donor, the copy number of the donor genome is obtained by dividing the measured copies / μL by two). The copy number of the recipient genome as determined by the dPCR assay (e.g., as the copy number of the recipient genome per μL) can also be adjusted as described above for the copy number of the donor genome. Next, the copy number of the donor genome in the sample from the transplant recipient is determined (e.g., the copy number of the donor genome per mL of sample, or per amount of cell-free nucleic acid in the sample) based on the volume used for the dPCR assay, the volume of the cell-free nucleic acid from the sample (e.g., the volume of the cell-free nucleic acid extracted from the sample from the transplant recipient), and the volume of the sample from the transplant recipient (e.g., the volume of the sample from the transplant recipient from which the cell-free nucleic acid was extracted). In some embodiments, the amount of donor-derived cell-free nucleic acid is determined using one or more or all of the following steps: (1) dividing the donor target copies / μl from the dPCR instrument by the number of donor target copies per haploid genome (if more than 1 donor target assay is combined in the fluorescence channel, also divided by the number of donor target assays in the fluorescence channel) to obtain the donor target copies / μl in the reaction; (2) calculating the total donor genome copies in the reaction by multiplying the donor target copies / μl in the reaction by the reaction volume; (3) dividing the total donor genome copies in the reaction by the volume of the nucleic acid sample used in the reaction to obtain the total donor genome copies per volume of nucleic acid sample; (4) multiplying the total donor genome copies per nucleic acid volume of the sample by the total volume of the nucleic acid sample obtained from the nucleic acid extraction to obtain the total donor genome copies obtained from the nucleic acid extraction; and (5) calculating the total donor genome copies per volume of plasma from the recipient by dividing the total donor genome copies obtained from the nucleic acid extraction by the volume of plasma used in the nucleic acid extraction.
[0087] In some embodiments, the amount of the cell-free nucleic acid in the donor source is based on the quantitative determination of the dPCR of both donor-specific nucleic acid and receptor-specific nucleic acid in the sample, and is determined as the ratio of the cell-free nucleic acid in the donor source to the total donor-specific nucleic acid and receptor-specific nucleic acid. In some embodiments, the copy number of the donor genome determined by dPCR determination (for example, as the copy number of the donor genome reacted per μL) is adjusted to the copy number of each donor-specific target in dPCR determination (for example, for the double copy target corresponding to the donor, the copy number of the donor genome determined by dPCR determination is divided by two). The copy number of the recipient genome determined by dPCR determination (for example, as the copy number of the recipient genome reacted per μL) can be adjusted as described above for the copy number of the donor genome. Then determine the ratio of the total combined copy number of the donor genome copy and the recipient genome and the donor genome. In some cases, determine the score or percentage of the total combined copy number of the donor genome copy and the recipient genome and the donor genome.
[0088] B. Organ, tissue or cell transplant rejection
[0089] For example, following transplantation of an organ, tissue, or cell, the recipient may experience immunoquiescence, a state characterized by absence or low levels of immune activity or absence of rejection-related clinical symptoms, such as biopsy-confirmed rejection, or significant changes in organ function, e.g., as indicated by elevated serum creatinine levels, decreased estimated glomerular filtration rate, abnormal echocardiogram results, or some other clinical problem indicating a clinical need for a biopsy.
[0090] Alternatively, the recipient may experience active rejection, which may be due to T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or a combination of the two (i.e., "mixed" rejection). ABMR refers to antibody-mediated rejection of an organ, tissue, or cell transplant, including but not limited to acute active antibody-mediated rejection, chronic active antibody-mediated rejection, and chronic stable antibody-mediated rejection. TCMR refers to cell or T-cell-mediated rejection of an organ, tissue, or cell transplant, including but not limited to TCMR IA, IB, IIA, IIB, critical TCMR, and chronic TCMR.
[0091] Therefore, in some embodiments, the state of the organ, tissue or cell transplant as determined by any method in the method provided herein can be the absence of rejection, for example, characterized by immune quiescence. In other embodiments, the state of the organ, tissue or cell transplant as determined by any method in the method provided herein can be the presence of rejection, such as active rejection, T cell-mediated rejection, antibody-mediated rejection or mixed rejection. In other embodiments, the state of the organ, tissue or cell transplant as determined by any method in the method provided herein can be the risk and possibility of prediction rejection, such as active rejection, T cell-mediated rejection, antibody-mediated rejection or mixed rejection.
[0092] Detection of transplant rejection
[0093] In some embodiments, the methods provided herein include detecting, predicting, diagnosing and / or monitoring the transplant rejection state of an organ, tissue or cell transplant from a donor in a transplant recipient. In some embodiments, the method includes detecting transplant rejection if the amount of donor-derived cell-free nucleic acid in the cell-free nucleic acid in a sample obtained from a transplant recipient (e.g., as determined according to the methods disclosed herein) exceeds a predetermined threshold.
[0094] A predetermined threshold generally refers to any predetermined level or range of levels, which indicates the presence or absence of a disease, or the presence or absence of a risk or possibility of the presence or absence of a disease, such as rejection or non-rejection. A predetermined threshold according to the present disclosure can take a variety of forms. It can be a single cutoff value, such as a median or mean value. As another example, a predetermined threshold can be determined from a baseline value before the presence of a disease, or the risk or possibility of the presence of a disease, or after a treatment process. Such a baseline can indicate a normal or other state in a transplant recipient that is not related to the risk or disease being tested. For example, a baseline value can be the level of a donor-derived cell-free nucleic acid (such as a donor-derived cell-free DNA) in a sample from a transplant recipient before transplantation, which is approximately zero or negligible, but can also indicate a baseline error in the system. In some embodiments, a predetermined threshold can be a baseline value of a transplant recipient being tested. When a predetermined threshold involves defining a significant change in the amount of a donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient, it can vary significantly. Those skilled in the art will recognize appropriate parameters and methods for determining a significant change in the amount of a donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient over time. Once appropriate analytical parameters are selected, determining changes in the amount of donor-derived cell-free nucleic acid (eg, DNA) in a transplant recipient over a period of time can inform the status of the transplant.
[0095] In some embodiments, the amount of donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient increases over time indicating transplant rejection or the risk or possibility of transplant rejection, the need to administer or adjust immunosuppressive therapy, immunosuppressive therapy for nephrotoxicity, infection, and / or the need to further study the transplant state. Without wishing to be bound by theory, it is believed that if the amount of donor-derived cell-free nucleic acid (e.g., DNA) increases over time in a transplant recipient, the cells of the transplant increasingly experience apoptosis and / or necrosis over time, indicating transplant rejection or the risk or possibility of transplant rejection.
[0096] In some embodiments, the amount of donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient decreases over time indicating transplant tolerance, the need to adjust immunosuppressive therapy (e.g., decrease), and / or the need to further study the transplant status. Without being bound by theory, it is believed that if the amount of donor-derived cell-free nucleic acid (e.g., DNA) decreases over time in a transplant recipient, the cells of the transplant gradually decrease over time experiencing apoptosis and / or necrosis, which indicates transplant tolerance, excessive immunosuppression, or appropriate immunosuppression.
[0097] In some embodiments, the amount of the cell-free nucleic acid (for example, DNA) of donor origin in transplant recipient does not change over time indicating a stable transplant rejection state and / or the chance of adjusting immunosuppressive therapy.Do not wish to be bound by theory, it is believed that if the amount of the cell-free nucleic acid (for example, DNA) of donor origin does not change over time in transplant recipient, then the cell without transplantation experiences apoptosis of steady state level over time, which indicates a stable transplant rejection state.Stable transplant rejection state can notify the state of the transplant during the time window of analysis, but may not notify the transplant towards the direction of rejection or tolerance.For example, the transplant can experience active rejection in the transplant recipient, but the stable transplant rejection state indicates that the rejection rate does not change during the time period it is analyzed (that is, the transplant rejection rate does not increase or decrease).Similarly, the transplant can experience active tolerance in the transplant recipient, but the stable transplant rejection state indicates that the tolerance rate does not change during the time period it is analyzed (that is, the transplant tolerance rate does not increase or decrease).
[0098] C. Administer or adjust immunosuppressive therapy
[0099] In some embodiments, the methods provided herein include treating transplant rejection of an organ, tissue or cell transplant from a donor in a transplant recipient and / or adjusting immunosuppressive therapy in a transplant recipient of an organ, tissue or cell transplant from a donor.
[0100] Immunosuppressive therapy generally refers to the administration of immunosuppressants or other therapeutic agents that suppress the immune response of the transplant recipient. The medical practice of immunosuppression in transplant recipients has developed into a regimen including preventive drug preparations, usually starting with induction therapy to consume lymphocytes, followed by maintenance drugs intended to inhibit the activation or replication of lymphocytes, such as corticosteroids, calcineurin inhibitors (such as tacrolimus) and additional inhibitors of lymphocyte replication (such as mycophenolate mofetil). After transplantation, the dose of immunosuppressants can be reduced over time to reduce the incidence and severity of side effects, such as the risk of increased infectious diseases, while still avoiding immune rejection of the transplant.
[0101] In some embodiments, immunosuppressive therapy may be administered or recommended in response to identification of rejection of an organ, tissue, or cell transplant, including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant. In other embodiments, the dose or frequency of immunosuppressive therapy may be increased or recommended in response to identification of rejection of an organ, tissue, or cell transplant, or the risk or possibility of rejection, including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant. For example, in response to identification of TCMR, steroid bolus therapy may be started (or recommended to be started) in terms of dose and / or frequency, or maintenance immunosuppressive therapy may be increased (or recommended to be increased). In another example, in response to identification of ABMR, plasma removal or intravenous immunoglobulin (IVIg) may be started (or recommended to be started).
[0102] In other embodiments, the immunosuppressive therapy dose or frequency may be maintained or recommended for maintenance in response to identification of the absence of rejection of an organ, tissue, or cell transplant (e.g., immunoquiescence). In other embodiments, the immunosuppressive therapy dose or frequency may be reduced or recommended for reduction in response to identification of the absence of rejection of an organ, tissue, or cell transplant (e.g., immunoquiescence). In other embodiments, the immunosuppressive therapy dose or frequency may be stopped or interrupted or recommended for stopping or interruption in response to identification of the absence of rejection of an organ, tissue, or cell transplant (e.g., immunoquiescence).
[0103] In other embodiments, the methods of the present disclosure may include modifying immunosuppressive therapy relative to the agent administered or recommended for administration. In some embodiments, for example, in response to the identification of rejection of an organ, tissue, or cell transplant, immunosuppressive therapy may replace (or be recommended to replace) another immunosuppressive therapy, which includes T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection. In other embodiments, for example, in response to the identification of rejection of an organ, tissue, or cell transplant, immunosuppressive therapy may be administered in combination with one or more additional immunosuppressive therapies (or be recommended to be administered in combination with one or more additional immunosuppressive therapies), which includes T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection.
[0104] Immunosuppressive therapies and modifications to immunosuppressive therapies (e.g., replacing one therapy with another, or combination therapies) can be selected based on various factors, such as the likelihood that the immunosuppressive therapy will alleviate or reduce rejection of an organ, tissue, or cell transplant, alleviate or reduce the symptoms of rejection of an organ, tissue, or cell transplant, reduce any direct or indirect pathological consequences of rejection of an organ, tissue, or cell transplant, reduce the rate of organ, tissue, or cell transplant rejection, ameliorate or mitigate the state of organ, tissue, or cell transplant rejection, improve the prognosis of an organ, tissue, or cell transplant, or slow the progression of organ, tissue, or cell transplant rejection.
[0105] It should be noted that the amount of donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient may not be the only factor considered when determining whether to administer or adjust immunosuppressive therapy. For example, for a transplant recipient that exhibits rejection of a transplant and increased severity of infection, it may be undesirable to increase or even maintain current immunosuppressive therapy. Therefore, it should be noted that the immunosuppressive therapy applied to a transplant recipient can be increased, decreased, or maintained, regardless of the determined amount of donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient, depending on the presence or absence of other controlled or active clinical factors. Therefore, additional factors that may be considered when selecting, administering, modifying, or adjusting immunosuppressive therapy include prevention, control, improvement, or reduction of adverse effects of immunosuppressive therapy, such as adverse events, undesirable side effects, toxicity, undesirable drug-drug interactions, undesirable symptoms, etc.
[0106] Exemplary immunosuppressive therapies that can be used according to the methods of the present disclosure include, but are not limited to, calcineurin inhibitors, mTor inhibitors, ACE inhibitors, anticoagulants, antimalarials, beta-blockers, corticosteroids, cardiovascular drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, including, for example, aspirin, azathioprine, B7RP-1-fc, brequinar sodium, campath-1H, celecoxib, chloroquine, coumarin, cyclophosphamide, cyclosporin A, DHEA, deoxyspergualin, dexamethasone, diclofenac, diflunisal, etodolac, everolimus, FK778, piroxicam, fenoprofen, flurbiprofen, heparin, hydralazine, hydroxychloroquine, CTLA-4 or LFA3 immunoglobulins, ibuprofen, indole Indomethacin, ISAtx-247, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, mepacrine, 6-mercaptopurine, meloxicam, methotrexate, mizoribine, mycophenolic acid derivatives, naproxen, oxaprozin, chloroquine, NOX-100, prednisone, methylprednisolone, rapamycin (sirolimus), sulindac, tacrolimus (FK506), thymocyte globulin, tolmetin, tripelimus, UO126, and antibodies, including, for example, alpha lymphocyte antibodies, adalimumab, anti-CD3, anti-CD25, anti-CD52, anti-IL2R, anti-TAC antibodies, basiliximab, daclizumab, etanercept, hu5C8, infliximab, OKT4 and natalizumab, or any combination thereof.
[0107] Administer or modify transplant-related therapy
[0108] The methods of the present disclosure can also be used to inform the need to administer or adjust other transplant-related therapies. Generally speaking, the amount of donor-derived cell-free nucleic acid (e.g., DNA) in a transplant recipient that exceeds a predetermined threshold can convey information about determining the need to administer or adjust other transplant-related therapies.
[0109] Other transplant-related therapies include treatments or therapies other than transplantation or immunosuppressive therapy, which are administered to transplant recipients to promote the survival of the transplant or to treat transplant-related symptoms (e.g., cytokine release syndrome, neurotoxicity). Examples of other transplant-related therapies include, but are not limited to, administration of antibodies, antigen-targeting ligands, non-immunosuppressive drugs, and other agents that stabilize or destabilize components of the transplant that are critical to the activity of the transplant or directly activate or inhibit one or more transplant activities. These activities may include the ability to induce, modify or attenuate immune responses, recognize specific antigens, replicate and / or induce damaged tissue repair.
[0110] Adjusting monitoring of transplant recipients
[0111] The method disclosed herein can also be used to notify the need to adjust the monitoring of the recipient of the transplant. Generally speaking, the amount of donor-derived cell-free nucleic acid (e.g., DNA) that exceeds a predetermined threshold in the transplant recipient can convey information about determining the need to adjust the monitoring of the recipient of the transplant. In some embodiments, as described above, determining that the state of the transplant conveys information about determining the need to adjust the monitoring of the recipient of the transplant.
[0112] Depending on the status of the transplant, the monitoring of the recipient can be adjusted accordingly. For example, the monitoring can be adjusted by appropriately increasing or decreasing the monitoring frequency. Monitoring can be adjusted by changing the monitoring method (e.g., by changing the metric or assay used to monitor the recipient).
[0113] D. Report
[0114] In some embodiments, the methods described herein may include generating and / or providing a report.
[0115] In some embodiments, the report includes an assessment or diagnosis of organ, tissue or cell transplant rejection status in a transplant recipient, such as determined according to the methods described herein. In some embodiments, the report indicates the presence of rejection of an organ, tissue or cell transplant, including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR) or mixed rejection of an organ, tissue or cell transplant. In some embodiments, the report indicates the risk or possibility of rejection of an organ, tissue or cell transplant, including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR) or mixed rejection of an organ, tissue or cell transplant. In some embodiments, the report indicates the absence of rejection of an organ, tissue or cell transplant, such as immune quiescence. In some embodiments, the report includes, for example, at least in part based on the detection of rejection of an organ, tissue or cell transplant according to the methods provided herein and suggesting the administration of immunosuppressive therapy to a transplant recipient, including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR) or mixed rejection of an organ, tissue or cell transplant, such as described in more detail above. In some embodiments, the report includes, for example, recommending an adjustment or modification of the immunosuppressive therapy administered to the transplant recipient based at least in part on the detection of the presence or absence of rejection of an organ, tissue, or cell transplant according to the methods provided herein, such as recommending an increase, decrease, or maintenance of the dose or frequency, or interruption or modification of the immunosuppressive therapy, as described in more detail above.
[0116] In some embodiments, the report indicates the presence of rejection of an organ, tissue, or cell transplant in the recipient (e.g., including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant), and includes a recommendation to administer immunosuppressive therapy to the transplant recipient, e.g., as described in more detail above. In some embodiments, the report indicates the presence of rejection of an organ, tissue, or cell transplant (e.g., including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant), and includes a recommendation to adjust the immunosuppressive therapy administered to the transplant recipient, e.g., increase the dose or frequency, or modify the immunosuppressive therapy, as described in more detail above. In some embodiments, the report indicates the risk or likelihood of rejection of an organ, tissue, or cell transplant in the recipient (e.g., including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant), and includes a recommendation to administer immunosuppressive therapy to the transplant recipient, e.g., as described in more detail above. In some embodiments, the report indicates a risk or likelihood of rejection of an organ, tissue, or cell transplant (e.g., including T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR or AMR), or mixed rejection of an organ, tissue, or cell transplant), and includes a recommendation to adjust the immunosuppressive therapy administered to the transplant recipient, e.g., to increase the dose or frequency, or to modify the immunosuppressive therapy, as described in more detail above. In some embodiments, the report indicates the absence of rejection of an organ, tissue, or cell transplant, and includes a recommendation to adjust or modify the immunosuppressive therapy administered to the transplant recipient, e.g., to maintain or reduce the dose or frequency, or to interrupt or modify the immunosuppressive therapy, as described in more detail above.
[0117] Reports according to the present disclosure may be in any suitable form, such as digital, electronic, web-based, or paper. In some embodiments, the report may be provided to one or more parties, such as a transplant recipient, a caregiver, a physician, a hospital, a clinic, a third-party payer, an insurance company, a government agency, and any combination thereof.
[0118] In some embodiments, the report may include information about the prognosis or potential or suggested treatment options. The report may include information about the possible effectiveness of the treatment options, the acceptability of the treatment options, or the rationality of applying the treatment options to the transplant recipient. For example, the report may include information or recommendations about the administration of a drug (such as an immunosuppressive therapy), as well as a recommended dosage or treatment regimen, and / or in combination with other drugs.
[0119] In some embodiments, a report can be generated and / or provided to a party in less than a day, or in any time between about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about one week, about two weeks, about three weeks, about four weeks, or about one month from obtaining or receiving a sample from a transplant recipient, or from determining the status of an organ, cell, or tissue transplant (e.g., the presence or absence of rejection of an organ, cell, or tissue transplant).
[0120] II. Cell-free nucleic acids
[0121] The methods provided herein involve analyzing cell-free nucleic acids (e.g., cell-free DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpins, DNA / RNA hybrids, RNA hairpins, and combinations thereof) from a transplant recipient to detect and monitor the transplant rejection status of an organ, tissue, or cell transplant in a transplant recipient.
[0122] Cell-free nucleic acid generally refers to nucleic acid present in or circulating outside the cell, such as, for example, nucleic acid present in the body fluid (e.g., blood, plasma, serum, urine, etc.) of a transplant recipient. Cell-free nucleic acid can originate from different positions in the cell. For example, cell-free nucleic acid (such as cell-free DNA) can be derived from, for example, nuclear DNA and / or mitochondrial DNA. Without wishing to be bound by theory, it is believed that cell-free nucleic acid is released from the cell via apoptosis or necrosis (i.e., cell death) of the cell. Therefore, without wishing to be bound by theory, it is believed that during transplant rejection, apoptosis or necrosis of cells from organs, tissues or cell transplants will cause donor-derived cell-free nucleic acid to be released into the body fluid of the transplant recipient. A transplant recipient experiencing transplant rejection can then have a cell-free nucleic acid population in its body fluid, which includes its own endogenous cell-free nucleic acid (cell-free nucleic acid of recipient origin) and cell-free nucleic acid (cell-free nucleic acid of donor origin) derived from the donor. Thus, as disclosed herein, assessing the level of donor-derived cell-free nucleic acid in a transplant recipient according to the methods of the present disclosure can be used to detect, prognose, diagnose and / or monitor the status of an organ, tissue or cell transplant.
[0123] In some embodiments, the method of the present disclosure includes, for example, determining the amount of donor-derived cell-free nucleic acid in a sample containing cell-free nucleic acid from a transplant recipient according to any one of the detection / quantification methods provided herein. As described in more detail below, the sample from the transplant recipient can be or is derived from any body fluid, including whole blood, plasma, serum, lymph, urine, oral swab, bone marrow, saliva, sweat, lung lavage fluid, tears, ear fluid, sputum, fluid bone marrow suspension, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, respiratory secretions, intestinal fluid or urogenital tract fluid. In some embodiments, the sample is or is derived from urine. In some embodiments, the sample is or is derived from whole blood or its fraction (e.g., serum or plasma). In some embodiments, the sample is or is derived from plasma. In some embodiments, the cell-free nucleic acid present in the sample can be completely receptor-derived, or can include a mixture of receptor-derived and donor-derived nucleic acids.
[0124] In some embodiments, the cell-free nucleic acid of donor origin is cell-free DNA of donor origin, and / or the cell-free nucleic acid of recipient origin is cell-free DNA of recipient origin. In some embodiments, the cell-free nucleic acid of donor origin is cell-free RNA of donor origin, and / or the cell-free nucleic acid of recipient origin is cell-free RNA of recipient origin. In some embodiments, the cell-free RNA comprises tissue-specific RNA transcripts. In some embodiments, the gene expression levels of cell-free RNA from transplant recipients can be analyzed to detect, predict, diagnose and / or monitor the status of organs, tissues or cell transplants.
[0125] A. Extraction
[0126] Cell-free nucleic acids (such as cell-free DNA or cell-free RNA) from samples of transplant recipients can be extracted prior to analysis according to the methods of the present disclosure. Methods for extracting cell-free nucleic acids (such as cell-free DNA or cell-free RNA) are known in the art, see, e.g., Current Protocols in Molecular Biology, latest edition. Exemplary non-limiting methods that can be used include the Triton-Heat-Phenol (THP) method (Xue et al., (2009) Clin. Chim. Acta 404, 100-104), the phenol-chloroform isoamyl alcohol isolation (PCI) protocol (Yuan et al., (2012) Yonsei Med. J. 53: 132; Schmid et al., (2005) Clin. Chem. 51, 1560-1561; and Hufnagl et al. (2013) J. Nucleic Acids Investig. 4, 1-3), and the salting-out method (Miller et al., (1988) Nucleic Acids Res. 16: 1215; Jorgez et al. (2006) Genet. Med. 8, 615-619).Other exemplary non-limiting methods for extracting cell-free nucleic acid are known in the art, see, for example, Cell-Free Plasma DNA as a Predictor of Outcome in Severe Sepsis and Septic Shock. Clin. Chem. 2008, Vol. 54, pp. 1000-1007; Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction. JCO 2005, Vol. 23, pp. 5205-5210; Circulating Nucleic Acids in Blood of Healthy Male and Female Donors. Clin. Chem. 2005, Vol. 51, pp. 1317-1319; Use of Magnetic Beads for Plasma Cell-free DNA Extraction: Toward Automation of Plasma DNA Analysis for Molecular Diagnostics. Clin. Chem. 2003, Vol. 49, pp. 1953-1955; Chiu et al. RWK, Poon LLM, Lau TK, Leung TN, Wong EMC, Lo YMD. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001; 47: 1607-1613; and Swinkels et al., Effects of Blood-Processing Protocols on Cell-free DNA Quantification in Plasma. Clinical Chemistry, 2003, Vol. 49, No. 3, 525-526. Any method known in the art for extracting cell-free nucleic acids can be used in the methods of the present disclosure.In some embodiments, extraction of cell-free nucleic acids (such as cell-free DNA or cell-free RNA) from a sample can be performed using a commercially available kit, such as a Qiagen QIAamp circulating nucleic acid kit, a BioChain cfPure cell-free DNA extraction kit, a ThermoFisher Scientific MagMax cell-free DNA isolation kit, a Roche MagNa Pure 24 system, a Zymo Quick-cfDNA serum and plasma kit, or a Macherey-Nagel NucleoSnap cfDNA kit, a NucleoSpin Gel and PCRClean-Up kit, or a NucleoSpin Plasma XS kit. In some embodiments, extraction of cell-free nucleic acids (such as cell-free DNA or cell-free RNA) from a sample is performed using a Qiagen QIAamp circulating nucleic acid kit.
[0127] In some embodiments, the quality, quantity (e.g., concentration or absolute amount), and / or fragment size of the cell-free nucleic acid (such as cell-free DNA or cell-free RNA) can be further assessed, e.g., prior to analysis according to the methods of the present disclosure. Quantification, quality analysis, and / or fragment size analysis of cell-free nucleic acid can be performed using any method known in the art, such as fluorescent dsDNA assay (e.g., using the Quant-iT PicoGreen dsDNA assay kit from ThermoFisher), using a fluorometer such as using a Qubit assay, real-time PCR, quantitative PCR, or digital droplet PCR (see, e.g., Rago et al., (2007) Cancer Res. 67, 9364–9370; Takai et al. (2015) Sci. Rep. 5: 18425; Rostami et al., (2020) Cell Rep. 31: 107830; He et al., (2019) Sci. Rep. 9: 5599), using a bioanalyzer (e.g., using a high sensitivity DNA microchip kit (Agilent Technologies) and an Agilent 2100 bioanalyzer). In some embodiments, the cell-free nucleic acid can also be assessed for the presence of modifications, such as methylation. Any suitable method known in the art for analyzing nucleic acid modifications may be used, such as bisulfite-based methylation analysis, for example using a kit such as the EpiTect Plus DNA Bisulfite Kit or the PyroMark PCR Kit from Qiagen.
[0128] In some embodiments, at least about 10ng, 20ng, 30ng, 40ng, 50ng, 100ng, 200ng, 300ng, 400ng, 500ng, 600ng, 700ng, 800ng, 900ng, 1000ng, 2000ng, 3000ng, 4000ng, 5000ng of any one or more of cell-free nucleic acid (e.g., cell-free DNA or RNA) can be obtained, for example, from a sample from a transplant recipient after extraction. In some embodiments, between about 50ng and about 5000ng, between about 100ng and about 4000ng, or between about 200ng and about 4000ng (including any value within each of the ranges) of cell-free nucleic acid (e.g., cell-free DNA or RNA) can be obtained, for example, from a sample from a transplant recipient after extraction. In some embodiments, the cell-free nucleic acid (e.g., cell-free DNA or RNA) for use in the methods of the present disclosure can have a concentration of at least about any of 0.01 ng / μL, 0.1 ng / μL, 0.5 ng / μL, 0.75 ng / μL, 1 ng / μL, 5 ng / μL, 10 ng / μL, 15 ng / μL, 20 ng / μL, 25 ng / μL, 30 ng / μL, 35 ng / μL, 40 ng / μL, 45 ng / μL, 50 ng / μL, 55 ng / μL, 60 ng / μL, 65 ng / μL, 70 ng / μL, or more, e.g., after extraction. In some embodiments, the cell-free nucleic acid (e.g., cell-free DNA or RNA) for use in the methods of the present disclosure can have a concentration of between about 1 ng / μL and about 100 ng / μL, between about 1 ng / μL and about 70 ng / μL, or between about 4 ng / μL and about 70 ng / μL, including any values within each of the recited ranges, for example, after extraction.
[0129] B. Amplification
[0130] Cell-free nucleic acids (such as cell-free DNA or cell-free RNA) isolated from samples obtained from transplant recipients can be amplified, for example, according to the methods of the present disclosure for use in downstream techniques and analyses.
[0131] Methods for amplifying nucleic acids are well known in the art. Amplification generally refers to any device, method or technique that can generate a copy of a nucleic acid. Amplification of cell-free nucleic acids (e.g., cell-free DNA or RNA) can involve, for example, isothermal amplification techniques such as loop-mediated isothermal amplification (LAMP) and polymerase chain reaction (PCR) techniques such as linear amplification (see USPN 6,132,997), rolling circle amplification, etc. Cell-free nucleic acids (e.g., cell-free DNA or RNA) can be amplified for downstream analysis by, for example, qPCR, dPCR or sequencing. In the case where the cell-free nucleic acid is cell-free RNA, the method may include, for example, a step of generating DNA from the cell-free RNA using a reverse transcriptase. Fluidigm Access Array TM The RainDance Technologies RainDrop system, or other techniques for multiplex amplification can be used for multiplex or highly parallel singleplex nucleic acid amplification. Amplification can involve the use of a high-fidelity polymerase, such as, for example, FastStart High Fidelity (Roche), Expand High Fidelity (Roche), Phusion Flash II (ThermoFisher Scientific), Phusion Hot Start II (ThermoFisher Scientific) KAPA HiFi (Kapa BioSystems), or KAPA2G (Kapa Biosystems).
[0132] Amplification can include initial PCR cycles, which add unique sequences to each individual molecule, called molecular indexing. Amplified nucleic acids can also undergo additional processes, such as indexing (also referred to as barcodes or tags). Methods for indexing nucleic acids are well known in the art and described herein. Indexing allows the use of multiple sequencing platforms, which are compatible with a variety of sequencing systems, such as Illumina HiSeq, MiSeq and ThermoFisher Scientific Ion PGM and Ion Proton. Multiple sequencing allows sequencing of nucleic acids from multiple samples in a single reaction by using indexes to specifically identify the sample source of the sequenced nucleic acids.
[0133] III. Sample
[0134] In some embodiments, the methods provided herein include determining the amount of donor-derived cell-free nucleic acid in one or more samples (eg, one or more biological samples, such as one or more samples comprising cell-free nucleic acid) from a transplant recipient.
[0135] Typically, the sample according to the method provided herein can be (or can be derived from) any body fluid, including whole blood, plasma, serum, lymph, peripheral blood mononuclear cells, urine, oral swabs, bone marrow, saliva, sweat, lung lavage fluid, tears, ear fluid, sputum, fluid from bone marrow suspension, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, respiratory secretions, intestinal fluid or urogenital tract fluid. In some embodiments, the sample is or is derived from urine. In some embodiments, the sample is or is derived from whole blood or its fraction (for example, serum or plasma). In some embodiments, the sample is or is derived from plasma. In some embodiments, the sample is or is derived from serum. In some embodiments, when the sample is (or is derived from) blood, serum or plasma, blood, serum or plasma are derived from the vein or arterial blood of the transplant recipient. In some embodiments, blood, serum or plasma are derived from the venous blood of the transplant recipient.
[0136] In some embodiments, a sample from a transplant recipient according to the present disclosure comprises cell-free nucleic acid. In some embodiments, the cell-free nucleic acid present in the sample can be entirely recipient-derived cell-free nucleic acid, or the cell-free nucleic acid present in the sample can include a mixture of recipient-derived cell-free nucleic acid and donor-derived cell-free nucleic acid.
[0137] In some embodiments, the method provided herein includes providing a sample from a receptor. In some embodiments, the method provided herein also includes obtaining a sample from a receptor, for example, to prevent sample and / or analyte degradation and / or contamination and entering a specially prepared container. Once a sample is obtained, it can be directly used, frozen or otherwise stored in a condition that maintains sample integrity (for example, the integrity of nucleic acid in the sample, such as the integrity of cell-free nucleic acid in the sample) and prevents sample degradation and / or contamination. The amount of the sample collected at a specific time can vary, and can depend on additional factors, such as any needs of repeated sample analysis. In some embodiments, obtain a sample of up to 50mL, 40mL, 30mL, 20mL, 10mL, 9mL, 8mL, 7mL, 6mL, 5mL, 4mL, 3mL, 2mL, 1mL, 0.5mL, 0.1mL. In some embodiments, obtain a sample of 0.1mL-1mL, 1mL-50mL, 2mL-40mL, 3mL-30mL or 4mL-20mL. In some embodiments, more than 1 mL, 5 mL, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, 50 mL, 55 mL, 60 mL, 65 mL, 70 mL, 75 mL, 80 mL, 85 mL, 90 mL, 95 mL, or 100 mL of sample may be obtained.
[0138] Sample can obtain once or more than once from the receptor of transplant.In the case of obtaining multiple samples from the receptor of transplant, the frequency of sampling can change.For example, after the initial sampling event, sample can be about once a day, about once every other day, about once every three days, about once a week, about once every two weeks, about once every three weeks, about once every monthly, about once every two months, about once every three months, about once every four months, about once every five months, about once every six months, about once every year or about once every two years or longer time acquisition.In some embodiments, one, two, three, four, five, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, two hundred, three hundred, four hundred or five hundred or more samples can be obtained from the receptor. In some embodiments, between one and five, between five and ten, between ten and twenty, between twenty and thirty, between thirty and forty, between forty and fifty, between fifty and sixty, between sixty and seventy, between seventy and eighty, between eighty and ninety, between ninety and one hundred, between one hundred and two hundred, between two hundred and three hundred, between three hundred and four hundred, or between four hundred and five hundred, or more samples can be obtained from the receptor.
[0139] In some embodiments, one or more samples can be obtained from the recipient of the transplant within a period of time, for determining according to the method disclosed herein, i.e., detecting, predicting, diagnosing and / or monitoring the state of an organ, cell or tissue transplant in the recipient. The time interval for sampling from the recipient of the transplant after the transplant event can vary. For example, exemplary sampling intervals are described in U.S. Application No. 14 / 658,061, which is hereby incorporated by reference in its entirety. For example, samples can be obtained from the transplant recipient at different times and different time periods for determining according to the method disclosed herein, i.e., detecting, predicting, diagnosing and / or monitoring the state of an organ, cell or tissue transplant in the recipient. In some embodiments, one or more samples can be obtained from the transplant recipient before the recipient receives an organ, cell or tissue transplant. In some embodiments, the sample may be taken from the recipient about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 1 year, about 2 years, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 1 year, about 2 years, about 3 months, about 4 months, about 1 month, about 2 months ...3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months In some embodiments, one or more samples can be obtained from a transplant recipient in about 1 year, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, about 15 years, about 16 years, about 17 years, about 18 years, about 19 years, about 20 years, about 21 years, about 22 years, about 23 years, about 24 years, about 25 years, about 26 years, about 27 years, about 28 years, about 29 years, about 30 years or any combination of any one of longer, one or more samples can be obtained from a transplant recipient. In some embodiments, one or more samples can be obtained from a transplant recipient in about three months after a transplant event, about six months after that, about nine months after that or less than one year. In some embodiments, samples can be obtained from a transplant recipient at different times before the first anniversary of a transplant event, when the first anniversary of a transplant event, or at different times after the first anniversary of a transplant event. For example, at the first anniversary after transplantation, samples can be obtained from the transplant recipient starting from the 12th month (i.e., the first anniversary of the transplantation event) and thereafter for a period of time. In some embodiments, the time period for obtaining samples from the transplant recipient is within the first few days after the transplantation from the donor to the recipient occurs. This can be used to monitor induction therapy. In some embodiments, the time period for obtaining samples from the transplant recipient is included in the gradual reduction of the immunosuppressive regimen administered to the recipient, which usually occurs during the first 12 months after the transplantation from the donor to the recipient occurs. In some embodiments, the time period for obtaining samples from the transplant recipient is included during the initial long-term immunosuppression maintenance phase, which can start about 12-14 months or earlier or later after the transplantation from the donor to the recipient has occurred.In some embodiments, the time period over which the sample is obtained from the transplant recipient includes the entire long-term maintenance period of the immunosuppressive regimen, which can be any time greater than 12 months or earlier or later after the transplant from the donor to the recipient has occurred.
[0140] In some embodiments, one or more samples are obtained from the recipient of the transplant twice a week within the first three weeks after transplantation. In some embodiments, one or more samples are obtained daily within the first 1 or 2 weeks after transplantation. In some embodiments, one or more samples are obtained once a week within the first three months after transplantation. In some embodiments, one or more samples are obtained once a month within the first year after transplantation. In some embodiments, one or more samples are obtained four times a year after the first year after transplantation.
[0141] In some embodiments, starting from the first anniversary of the transplantation event (i.e., 12 months after the transplantation event), samples are obtained from the recipient of the transplant for one to three consecutive months, providing a total of four to six samples obtained within a three-month time interval for analysis, and collecting samples approximately every two weeks. In some embodiments, starting from the first anniversary of the transplantation event (i.e., 12 months after the transplantation event), samples are obtained from the transplant recipient once a week for one to three consecutive months, providing a total of twelve samples obtained within a three-month time interval for analysis. The total duration of obtaining samples from the recipient of the transplant and the frequency of obtaining such samples can vary and will depend on multiple factors, such as clinical progress. For example, the recipient of the transplant can obtain samples within its life span. For a given recipient of a transplant, those skilled in the art will be able to determine appropriate sampling time and frequency.
[0142] In some embodiments, the methods provided herein include providing one or more samples from a subject, eg, for use according to the methods of the present disclosure.
[0143] IV. Donor and Recipient
[0144] The methods disclosed herein include detecting, predicting, diagnosing and / or monitoring the transplant rejection state of an organ, tissue or cell transplant from a donor in a transplant recipient; treating the transplant rejection of an organ, tissue or cell transplant from a donor in a transplant recipient; and / or adjusting immunosuppressive therapy in a transplant recipient of an organ, tissue or cell transplant from a donor.
[0145] In some embodiments, an organ, tissue or cell transplant according to the present disclosure is a cross-species transplant (i.e., a xenogeneic or allogeneic transplant), wherein the organ, tissue or cell transplant donor is a species different from the transplant recipient. Therefore, in some embodiments, the methods of the present disclosure include detecting, predicting, diagnosing and / or monitoring the status of a cross-species, xenogeneic or allogeneic organ, tissue or cell transplant, treating transplant rejection of a cross-species, xenogeneic or allogeneic organ, tissue or cell transplant, and / or adjusting immunosuppressive therapy in a transplant recipient of a cross-species, xenogeneic or allogeneic organ, tissue or cell transplant, wherein the organ, tissue or cell transplant donor is a species different from the transplant recipient.
[0146] In some embodiments, the transplant recipient and the transplant donor are animals. In some embodiments, the transplant recipient and / or the transplant donor are vertebrates. In some embodiments, the transplant recipient and / or the transplant donor are mammals. In some embodiments, the transplant recipient and / or the transplant donor are non-human mammals. In some embodiments, the transplant recipient is a person, and the transplant donor is a non-human animal, such as a non-human vertebrate or a non-human mammal. In some embodiments, the transplant recipient is a non-human animal, such as a non-human vertebrate or a non-human mammal, and the transplant donor is a humanized non-human organ. In some embodiments, the non-human animal is a non-human primate, a cow, a horse, a pig, a sheep, a goat, a dog, a cat, a rodent, a bird, a reptile or other non-human animal. In some embodiments, the non-human mammal is a non-human primate, a cow, a horse, a pig, a sheep, a goat, a dog, a cat, a rodent or other non-human mammal. In some embodiments, the rodent is a mouse, a rat, a squirrel, a prairie dog, a porcupine, a beaver, a guinea pig, a hamster or another rodent. In some embodiments, the non-human primate is a monkey or ape. In some embodiments, the non-human primate is a chimpanzee, a bonobo, a gorilla, an orangutan, a rhesus monkey, a crab-eating monkey, a pig-tailed monkey, an African green monkey, a marmoset, a capuchin, a spider monkey, a black-tailed monkey, a baboon, a squirrel monkey, an owl monkey, or another non-human primate. In some embodiments, the transplant recipient is a human, and the transplant donor is a pig. In some embodiments, the pig is a wild boar (Sus scrofa), a domestic pig (Sus scrofa domesticus), a warthog (SPhacochoerusaethiopicus), a red river pig (Potamochoerusporcusporcus), an African wild boar (Potamochoerusporcus), a Southeast Asian warthog (Babirousababyrussa) species. In some embodiments, the pig is a Hanford pig, a miniature or micro pig, a Yucatan pig, a Yucatan micro pig, a Sinclair pig, a Gottingen pig, a Duroc pig, a Yorkshire pig, a Landrace pig, or a combination, hybrid, or cross-species thereof.
[0147] In some embodiments, the donor and / or recipient is genetically modified, or comprises one or more genetically modified cells, organs or tissues. In some embodiments, the organ, tissue or cell transplant is genetically modified. Such genetic modifications may include, for example, gene inactivation or complete gene knockout; and / or genetic integration or expression of a recipient or donor, or non-recipient or non-donor gene that the original genome of the transplant donor does not have.
[0148] In some embodiments, the transplant is derived from an adult (e.g., an adult human or non-human animal). In some embodiments, the transplant is derived from a fetus, an embryo, an embryonic stem cell, an induced pluripotent stem cell, a child or an adolescent, a teenager or a young adult. In some embodiments, the transplant is derived from a male or female.
[0149] V. Organ, cell and tissue transplants
[0150] The methods of the present disclosure include detecting, predicting, diagnosing and / or monitoring the transplant rejection status of an organ, tissue or cell transplant from a donor in a transplant recipient.
[0151] In some embodiments, the transplant according to the present disclosure is a transplant of one or more organs. In some embodiments, the organ is a solid organ or a hollow organ. In some embodiments, the transplant is a complete organ or part of an organ. In some embodiments, the organ can be any one of kidney, pancreas, liver, heart, lung, intestine, sac, adrenal gland, appendix, brain, ear, esophagus, eye, gallbladder, bladder, small intestine or large intestine, mouth, muscle, nose, parathyroid, pineal gland, pituitary gland, spleen, stomach, thymus, thyroid gland, trachea, uterus or appendix. In some cases, the organ is a glandular organ. For example, the organ can be an organ of the digestive system or the endocrine system. In some cases, the organ can be both an endocrine gland and a digestive organ. In some cases, the organ can be derived from endoderm, ectoderm, primitive endoderm or mesoderm. In some embodiments, the transplant is a vascularized composite transplant. In some embodiments, the organ transplant is a complete organ, a fragment of a complete organ, a ruptured organ or a cell from an organ.
[0152] In some embodiments, the transplant is a kidney transplant. A kidney transplant may also be referred to as a renal transplant. In some embodiments, the kidney transplant is derived from a deceased donor or a living donor. In some embodiments, the kidney is transplanted together with the pancreas. In some embodiments, the kidney transplant is derived from a porcine donor.
[0153] In some embodiments, the transplant is a heart transplant. A heart transplant may also be referred to as a cardiac transplant. In some embodiments, the heart transplant is derived from a porcine donor.
[0154] In some embodiments, the transplant according to the present disclosure is a transplant of one or more cells. In some embodiments, one or more cells are taken directly from a donor to be administered to a recipient; one or more cells are taken from a donor and genetically engineered before being administered to a recipient; one or more cells are taken from a donor and cultured before being administered to a recipient; one or more cells are taken from a donor and subjected to a manufacturing process before being administered to a recipient; or a combination thereof. One or more cells may also be stored (e.g., "ready-made" cells) before being administered to a recipient. In some embodiments, one or more cells are blood cells, stem cells, cardiomyocytes, neurons, lymphocytes, natural killer (NK) cells, NK T cells, T regulatory (T-reg) cells, neurons, macrophages, dendritic cells, islet cells, or any combination thereof. In some embodiments, blood cells may include hematopoietic stem cells (ie, HSC), T cells, B cells, chimeric antigen receptor (CAR) T cells, NK cells, NK T cells, tumor infiltrating lymphocytes (TILs), and any combination thereof. In some embodiments, one or more cells are CAR T cells, universal CAR T cells (ie, where CAR binds to antibodies that bind to specific antigens), split CAR T cells (ie, where dimerizers activate CAR T cell function), activatable CAR T cells, suppressive CAR T cells, multiphase CAR T cells (ie, where CAR must bind to multiple specific antigens and / or agents to induce T cell activation), tumor infiltrating lymphocytes, regulatory T cells, genetically modified T cells, T cells with genetically modified or synthetic T cell receptors (TCR), antigen-specific T cells (eg, EBV, HPV, BKV, CMV, etc.), antigen-specific T cells, neoantigen-specific T cells, or any cells separated from a donor. In some embodiments, one or more cells are administered as bone marrow, cord blood, or purified cells. In some embodiments, one or more cells are bone marrow cells. In some embodiments, one or more cells are cord blood cells. In some embodiments, the transplant comprises stem cells. In some embodiments, stem cells are administered as bone marrow, cord blood, or purified stem cells. In some embodiments, stem cells are derived from donors. In some embodiments, stem cells are administered as hematopoietic cell transplants. In some embodiments, blood cells include one or more of white blood cells (e.g., monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, etc.), red blood cells (erythrocytes), and platelets. In some embodiments, blood cells are administered as a transfusion (e.g., whole blood transfusion), a transfusion of a single component of blood, or a transfusion of purified cells such as white blood cells (e.g., monocytes, lymphocytes, neutrophils, eosinophils, basophils, or macrophages), red blood cells (erythrocytes), or platelets.In some embodiments, one or more cells are derived from an organ (e.g., an organ described herein or any other organ known in the art). In some embodiments, one or more cells are pancreatic cells, hepatocytes, cardiomyocytes, kidney cells, nervous system cells, etc.
[0155] In some embodiments of any method of the present disclosure, the transplant comprises stem cells. In some embodiments, the stem cells are embryonic stem cells, tissue-specific stem cells, induced pluripotent stem cells, hematopoietic stem cells, mesenchymal stem cells, skeletal stem cells, myogenic stem cells, cardiac stem cells, neural stem cells, epidermal stem cells or intestinal stem cells. In some embodiments, the stem cells are hematopoietic stem cells, embryonic stem cells, adult stem cells, pluripotent stem cells, multipotent stem cells, neuronal stem cells, cardiac stem cells, cells derived from umbilical cord blood or induced pluripotent stem cells.
[0156] In some embodiments, the one or more cells are gallbladder cells, cardiomyocytes, glomerular cells (e.g., parietal cells, podocytes), renal proximal tubule brush border cells, thin lamella cells of the loop of Henle, thick ascending limb cells, renal distal tubule cells, renal collecting duct cells, interstitial renal cells, enterocytes, goblet cells, enterocytes, caveolae cells, enteroendocrine cells, ganglionic neurons, parenchymal cells, non-parenchymal cells, hepatocytes, sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, muscle cells, pancreatic beta cells, endothelial cells, or exocrine cells, or any combination thereof.
[0157] In some embodiments, one or more cells are genetically engineered, and / or subjected to a manufacturing process, and / or cultured before being applied to a recipient. In some embodiments, the transplant of one or more cells comprises multiple types of cells. In some embodiments, the transplant comprises one or more cells that are genetically distinguishable from each other. In some embodiments, the transplant of one or more cells comprises two or more independent administrations. For example, a cell type can be administered in the first administration, and a second cell type can be administered in the second administration.
[0158] In some embodiments, the graft according to the present disclosure is a graft of tissue. Exemplary tissues include, but are not limited to, connective tissue, epithelial tissue, muscle tissue, neural tissue, lymphatic tissue, blood or blood components, adipose tissue, cartilage, dense fibrous tissue, skeletal muscle, myocardium, or smooth muscle. Muscle tissue may include myofiber or myocyte. In some embodiments, the tissue is cornea, tendon, heart valve, vein or artery, skin, bone, birth tissue, or a portion, fragment, and / or combination thereof. In some embodiments, birth tissue is placental tissue, amniotic tissue, chorionic tissue, amniotic fluid tissue, umbilical cord tissue, umbilical cord vein, or umbilical cord jelly. In some cases, the tissue is bone or tendon (both referred to as musculoskeletal grafts).
[0159] VI. Additional Analysis
[0160] The methods of the present disclosure may be performed in addition to, or in conjunction with, other analyses of samples from transplant recipients and / or transplant donors.
[0161] In some embodiments, the presence or level of an infectious agent in a transplant recipient is tested. Infectious agents that can be tested include, for example, viruses; bacteria such as Pseudomonas aeruginosa, Enterobacteriaceae, Nocardia, Streptococcus pneumonia, Staphylococcus aureus, and Legionella; fungi such as Candida, Aspergillus, Cryptococcus, Pneumocystis carinii; or parasites such as, for example, Toxoplasma gondii. In some embodiments, the presence or level of a viral infectious agent in a transplant recipient is tested. Viral biomarkers can be analyzed in nucleic acids obtained from samples from a transplant recipient to determine the presence or level of a virus in a transplant recipient. Testable viruses include, for example, cytomegalovirus, Epstein-Barr virus, Anelloviridae, and BK virus. The test results of the presence or level of the virus can be used to classify the immune status of the transplant recipient and / or determine the infection status of the transplant recipient. In some embodiments, in transplant recipients classified as having a high risk of clinically significant infection, immunosuppressive therapy can be reduced or at least not increased. In some embodiments, in transplant recipients classified as having a low risk of clinically significant infection, immunosuppressive therapy can be increased or at least not reduced. It should be noted that since other clinical factors can inform the decision to adjust immunosuppressive therapy, the transplant recipient can increase, reduce or maintain the immunosuppressive therapy currently administered to it, regardless of the test results of the presence or level of the virus and / or the classification of the risk of clinically significant infection.
[0162] In some embodiments, the method of the present disclosure includes performing gene expression analysis in a sample from a transplant recipient. In some embodiments, gene expression analysis is performed on peripheral blood mononuclear cells (PBMC) from the recipient. In some embodiments, gene expression analysis is performed on whole blood samples or portions thereof from the recipient. In some embodiments, gene expression analysis is performed on selected genes that provide information related to the state of cells, organs or tissue transplants in the transplant recipient. In some embodiments, gene expression analysis is performed using any suitable method known in the art, such as RNA sequencing, microarray methods, Nanostring analysis systems and quantitative real-time PCR. In some embodiments, expression analysis is performed using the AlloMap test. The AlloMap test involves using RNA separated from PBMC for quantitative real-time polymerase chain reaction (qRT-PCR) determination. The expression of a selected number of genes is analyzed, and the gene expression data is used to provide information related to the state of cells, organs or tissue transplants in the transplant recipient. The AlloMap test is known in the art. The results of gene expression analysis (e.g., obtained using the AlloMap test or any other suitable method) can be used in conjunction with the methods of the present disclosure, with or without methods that define a single score from a combination of tests, to determine the status of a cell, organ, or tissue graft in a transplant recipient and / or to inform the need to administer immunosuppressive therapy or to adjust immunosuppressive therapy administered to a transplant recipient.
[0163] In some embodiments, the methods of the present disclosure involve determining a single score that can be used to communicate the status of a cell, organ, or tissue graft in a transplant recipient.
[0164] In some embodiments, the method disclosed herein relates to determining a combined score that can be used to communicate the state of cells, organs or tissue transplants in a transplant recipient. The combined score is generally calculated based on the results of multiple (e.g., two or more) assays for detecting the state of cells, organs or tissue transplants in a transplant recipient. For example, the combined score can be calculated based on the results of the determined levels of donor-derived cell-free nucleic acids (e.g., DNA) in a transplant recipient and, for example, gene expression profiling assays (such as AlloMap tests) as described above. The combined score can be calculated based on a single sample taken from a transplant recipient, or they can be based on samples taken from a transplant recipient within a certain time interval. The combined score can be used to determine the state of cells, organs or tissue transplants in a transplant recipient and / or notify the need to administer immunosuppressive therapy or adjust the immunosuppressive therapy administered to the transplant recipient.
[0165] Additional biomarker analyses, gene expression assays, and other assays for determining (i.e., detecting, predicting, diagnosing, and / or monitoring) the status of a cell, organ, or tissue graft in a transplant recipient and / or determining the need for administering or adjusting immunosuppressive therapy may also be used in addition to or in conjunction with the methods of the present disclosure, with or without methods of defining a single score from a combination of tests, as will be readily apparent to those skilled in the art.
[0166] Additional analysis may be performed to identify markers of new, metastatic, or recurrent cancers in transplant recipients. Primers may be designed to amplify regions where genetic mutations are known to occur, thereby providing early detection of cancer by identifying known tumor-associated mutations. This may be advantageous, at least in part, because transplant recipients may be at an elevated risk of developing certain malignancies due to immunosuppression.
[0167] VII. Kits of the Disclosure
[0168] Also provided herein are kits for use in any of the methods described herein.
[0169] In one aspect, provided herein is a kit for detecting, predicting, diagnosing and / or monitoring the transplant rejection state of an organ, tissue or cell transplant from a donor in a transplant recipient, wherein the donor and the recipient belong to different species. In some embodiments, the kit comprises a reagent for use according to the method disclosed herein. For example, in some embodiments, the kit comprises a reagent for analyzing a cell-free nucleic acid separated from a transplant recipient, as described herein. In some embodiments, the kit may comprise a reagent for performing qPCR, dPCR or sequencing methods (such as NGS or HTS), such as described above. Such reagents may include primers (for example, for use in qPCR or dPCR methods), probes or dyes (for example, for use in qPCR or dPCR methods), reagents for sequencing library preparation, reagents for amplifying nucleic acids (for example, polymerases, buffers, etc.), reagents for performing nucleic acid extraction (if extraction is necessary) from a sample, etc. In some embodiments, the kit comprises one or more PCR reaction oligonucleotide primers and probe sets, which hybridize with donor-specific or receptor-specific target sequences in cell-free nucleic acids from, for example, a transplant recipient. In some embodiments, one or more PCR reaction oligonucleotide primers and probe sets of the kit are used for qPCR or digital PCR quantification of donor-derived cell-free nucleic acid as absolute copies of donor-derived cell-free nucleic acid in a sample or with reference to the total cell-free nucleic acid analyzed. In some embodiments, one or more PCR reaction oligonucleotide primers and probe sets of the kit are used for qPCR or digital PCR quantification of donor-derived cell-free nucleic acid as absolute copies of donor-derived cell-free nucleic acid in a sample, or as a ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid in a sample. In some embodiments, one or more PCR reaction oligonucleotide primers and probe sets of the kit are used for digital PCR quantification of donor-derived cell-free nucleic acid, with reference to the sample amount analyzed or with reference to the total cell-free nucleic acid analyzed. In some embodiments, the kit may contain reagents sufficient to analyze a single sample. In some embodiments, the kit may contain reagents sufficient to analyze several samples.
[0170] In some embodiments, the kit may include instructions for specifying target values and control materials that can be used in combination with the reagents and instructions provided in the kit. In some embodiments, the kit also includes controls for use according to the methods of the present disclosure. For example, in some embodiments, the kit also includes a control sample containing a known amount of nucleic acid (e.g., cell-free nucleic acid).
[0171] In some embodiments, the kit also includes instructions for use according to the methods of the present disclosure. Instructions for performing any of the methods described herein may be included. For example, in some embodiments, the kit includes instructions for using the kit and data analysis to determine the amount of donor-derived cell-free nucleic acid.
[0172] In some embodiments, the kit further includes instructions and specifications regarding the quality of the input material or the method of preparing the input.
[0173] In some embodiments, the kit includes software instructions for analyzing sequence data (e.g., sequence reads) or PCR data (e.g., data from qPCR or dPCR), for example, to determine the amount of donor-derived cell-free nucleic acid in the cell-free nucleic acid obtained from a sample from a transplant recipient. In some embodiments, the kit includes instructions for accessing software that can be used to perform a statistical analysis of donor-derived cell-free nucleic acid in the cell-free nucleic acid obtained from a sample from a transplant recipient, such as instructions for downloading and / or installing the software.
[0174] VIII. Software, Systems and Equipment
[0175] Certain aspects of the method described herein for detecting, predicting, diagnosing and / or monitoring the transplant rejection state of an organ, tissue or cell transplant from a donor in a transplant recipient (wherein the donor and the recipient belong to different species) can be performed by a computer system or device. For example, in some embodiments, the step of analyzing sequence data (e.g., sequence reads) or PCR data (e.g., data from qPCR or dPCR) to determine the amount of donor-derived cell-free nucleic acid in the cell-free nucleic acid obtained from a sample from a transplant recipient can be performed using a computer system or device. Software for performing the methods described herein is also provided herein.
[0176] The above-mentioned embodiments of the present disclosure can be implemented in various ways. For example, some aspects of the embodiments can be implemented using hardware, software or a combination thereof. When implemented in software, the software code can be executed on any suitable processor or processor set, whether provided in a single computer or distributed in multiple computers. It should be understood that any component or set of components that perform the above-mentioned functions can be generally considered to be one or more controllers that control the functions discussed above. One or more controllers can be implemented in various ways, such as using dedicated hardware, or using general-purpose hardware (e.g., one or more processors) that use microcode or software programming to perform the above-mentioned functions.
[0177] In this regard, it should be noted that the specific implementation of the various features of the present disclosure may use at least one non-transitory computer-readable storage medium (e.g., computer memory, floppy disk, compact disc, magnetic tape, etc.) encoded with a computer program (i.e., multiple instructions) that performs the functions and methods discussed above when executed on a processor. The computer-readable storage medium may be transportable so that the program stored thereon can be loaded onto any computer resource to implement certain aspects of the present disclosure discussed herein. In addition, it should be noted that references to computer programs that perform the functions discussed above when executed are not limited to applications running on a host computer. Instead, the term computer program is used herein in a general sense to refer to any type of computer code (e.g., software or microcode) that can be used to program a processor to implement certain aspects of the present disclosure.
[0178] Example
[0179] The present invention will be more fully understood by reference to the following examples. However, they should not be counted as limiting the scope of the present invention. It should be understood that the embodiments and embodiments described herein are for illustrative purposes only, and various modifications or changes thereof will be suggested to those skilled in the art, and will be included in the spirit and scope of the application and the scope of the appended claims.
[0180] Example 1: Method for non-invasive monitoring of organ graft health in cross-species transplantation
[0181] This example describes a digital polymerase chain reaction (dPCR) and sequencing-based method for non-invasive monitoring of cross-species organ transplants using cell-free DNA (cfDNA) from transplant recipients.
[0182] In the method for cross-species transplant monitoring described below, genetically modified pigs are used as exemplary organ donors, and humans are used as exemplary organ recipients. Pigs have been genetically modified (Revivicor, a United Therapeutics subsidiary) to not express four pig genes and to express six human genes in addition. These modifications are considered and found to represent negligible changes in donor genome size. Therefore, all calculations herein are based on pig genomes, as publicly available for wild boars.
[0183] Generally speaking, the modification of the genome of the transplant donor animal can include gene inactivation or complete gene knockout, and / or the genetic integration and expression of additional human or non-human genes that the original genome of the transplant donor animal does not have. Most (if not all) genetic modifications are used to mitigate the purpose of potentially aggressive immune responses triggered by the immune system of the transplant recipient.
[0184] A dPCR-based method for non-invasive monitoring of cross-species organ transplants
[0185] General approach
[0186] Single copy target detection and multi-copy target detection assays were designed for singleplex and multiplex dPCR assays as outlined in Table 1. Accuracy was calculated as the percentage of measured copies relative to expected copies based on input DNA, as measured by the qubits.
[0187] Table 1. Overview of target detection designs for singleplex and multiplex dPCR assays .
[0188]
[0189] Primer and probe design
[0190] Design PCR primers and probes to quantitatively detect human-specific genomic DNA sequences and pig-specific genomic DNA sequences. Exemplary PCR primers and fluorophore-labeled probes are shown in Table 2 below. Genomic DNA sequences in the intron region of the gene are advantageously selected as at least a portion of the target region for PCR primer design because they are more likely to show diversity between the pig genome and the human genome. Primer and probe design are selected using, for example, the Primer3 program (see primer3.org), with target assay parameters of: amplicon size of 60-110 base pairs, primer melting temperature (T m ) is 60°C, and the probe T m It is 65℃-70℃.
[0191] Table 2. Examples of methods for detecting and quantifying human-specific genomic DNA sequences and pig-specific genomic DNA sequences PCR primers and fluorophore-labeled probes In one embodiment of the invention, a two-copy porcine target assay as described herein detects two copies of a PCR target per haploid genome. In another embodiment of the invention, an 8-copy porcine target assay as described herein detects 8 copies of the same PCR target per haploid genome.
[0192]
[0193] In order to ensure that there is no cross-species reaction, the unique amplicon product of PCR primers is checked for one genome (e.g., pig) using a computer simulation PCR program, and the absence of amplicon product is checked for another genome (e.g., people). The target genome (e.g., pig genome) is divided into base pair (bp) segments, such as segments of 80bp, by calculation, and the segments are mapped back to the target genome to identify the multi-mapped segments. The multi-mapped segments are compared with non-target genomes, and any comparison is discarded. In some cases, the remaining multi-mapped segments are filtered to remove fragments, such as fragments with high or low GC content or fragments aligned with repeated masking regions, or to remove, for example, undesirable regions such as non-exon regions. "LOC" genes (i.e. genes with uncertain functions, no official symbols and / or no orthologs) are discarded, and overlapping segments are merged. The remaining segments are submitted to Primer3 design software, and the 0th primer set output of each segment is verified by computer simulation PCR to confirm the absence of multiple hits in the target genome and the hits in the non-target genome. Among the designs generated by Primer3, only those with a minimum spacing of 1 kilobase between segments were selected for experimental evaluation.
[0194] The probes were labeled with the same fluorescent dye for singleplex dPCR assays or with different fluorescent dyes for multiplex dPCR assays (described below).
[0195] For multi-copy target detection assays, pig-specific multi-gene families were identified, and PCR primers / probes were designed to detect multiple copies of target sequences in the pig genome, but no material in the human genome was detected. For pig-specific PCR assay primer and probe design, the genomic sequences of multi-gene families (e.g., rRNA, Hox, histone and tubulin gene families) were searched to find regions with high diversity between the pig and human genomes. Compared with single-copy target detection assays, multi-copy target detection assays have an increased number of positive partitions of the pig genome, which is important when pig cfDNA is present in a sample with very low copies. For example, the pig double-copy target detection assay detects two pig target copies per haploid genome, and therefore, compared with the single-copy target detection assay, up to twice the pig-specific partition counts are generated.
[0196] Method 1A : Singleplex dPCR assay detecting a single copy human-specific target and a single copy porcine-specific target.
[0197] Different amounts of cfDNA input in each sample (e.g., up to 120 ng) were measured using a human-specific dPCR assay for detecting a single-copy human-specific target and a pig-specific dPCR assay for detecting a single-copy pig-specific target. According to the standard protocol recommended by the manufacturer, 1x multiplex PCR MasterMix, 0.5 μM forward and reverse primers, and 0.3 μM FAM-labeled probes were used on a Stilla Naica system in a 25 μl reaction on a Crystal Droplet dPCR sapphire chip. dPCR results were obtained with a Crystal Droplet dPCR reader and analyzed with Crystal Droplet dPCR Miner software. The pig and human genome copy concentrations were normalized to the input cfDNA amount (ng), and the pig genome copy percentage was calculated relative to the total copies of the pig and human genomes in the sample.
[0198] Method 1B : Singleplex dPCR assay detecting single copy human-specific target and multiple copies porcine-specific target.
[0199] As described above for Method 1A, separate single-plex dPCR assays for detecting single-copy human-specific targets and multi-copy pig-specific targets were performed. To determine the pig genome copy concentration, the measured pig copy number was divided by the copy number of the pig-specific target per haploid genome (e.g., if a double-copy target is used in the pig assay, the measured pig copy number is divided by 2). Pig and human genome copies per μl are added together, and the percentage of pig genome copies is calculated relative to the total copies of the pig and human genomes in the sample. The multi-copy pig-specific target detection assay improves quantitative accuracy and sensitivity.
[0200] Method 2A : A multiplex dPCR assay that detects one or more single-copy human-specific targets and one or more single-copy and / or multi-copy porcine-specific targets using unique fluorescent dyes to distinguish all different targets or to distinguish between two species.
[0201] For different component assay probes, separate human target-specific and porcine target-specific assays (e.g., as described above for methods 1A and 1B) are selectively combined into a single multiplex assay using different fluorescent dye labels (e.g., FAM, HEX, ATTO 550, ROX, Cy5, Cy5.5, SUN). The genome copy concentration from each component is corrected for the genome copy concentration of the multicopy target assay (if any), averaged for human and porcine genome copy concentrations, and the porcine genome copy percentage is calculated relative to the total copies of the porcine and human genomes in the sample. Therefore, in method 2A, more targets are used to increase the number of positive partitions of the donor and improve assay accuracy and sensitivity.
[0202] Method 2B : A multiplex dPCR assay that detects 1 or more single-copy human-specific targets and at least 1 multi-copy porcine-specific target using non-unique fluorescent dyes for targets within the same species.
[0203] The multiplex dPCR assay was designed as described above for Method 2A, except that at least 1 multi-copy target assay was used in a single dPCR assay reaction, either labeled with different fluorescent dyes or labeled with the same fluorescent dye. Thus, in Method 2B, multiple pig-specific target PCR assays were detected using multiple fluorescent channels or a single fluorescent channel to increase the number of positive partitions for determining pig donor-derived cfDNA and improve assay accuracy and sensitivity, assuming that different genomic targets are separated from each other and can be independently amplified in different droplets in the dPCR assay.
[0204] Data analysis
[0205] For methods 1A-1B and 2A-2B, as described above, the output from the dPCR reactions (i.e., porcine-specific target sequence copies per μL reaction and human-specific target sequence copies per μL reaction) was divided by the number of target sequence copies per haploid genome determined for each time, and the genome copies per μL concentration were calculated. For relative concentrations, the fraction or percentage of porcine genome copies was calculated relative to the total genome (e.g., the total number of human and porcine genome copies).
[0206] The number of porcine genomes can also be determined and reported as an absolute value per unit of sample input, for example as the number of porcine genome copies per ngcfDNA or per milliliter (mL) of plasma.
[0207] For absolute concentrations, the pig target sequence copies per μl from the dPCR instrument are first adjusted by the target sequence copy number for each target in the genome (divided by the target sequence copy number). Then, the volume used in the dPCR reaction is used to calculate the pig genome equivalent cfDNA copies per ml of plasma, in addition to the volume of DNA eluted from the extraction and the volume of plasma used in the DNA extraction. Alternative methods for determining absolute concentrations include, but are not limited to, obtaining pig (target) copies per μl (cp / μl) from the dPCR instrument, calculating the pig genome cp / μl by dividing the pig cp / μl by the target copy number per haploid genome and the number of assays (if more than 1 assay is combined in the fluorescent channel), determining the pig genome copies entering the dPCR reaction, and measuring the pig genome cp / ml plasma. The specific steps of a method for determining the absolute number of sequences of pig origin are as follows:
[0208] 1. Take the porcine target copies per μl from the dPCR instrument and divide by the number of porcine target copies per haploid genome (if more than 1 porcine target assay is combined in the fluorescence channel, also divide by the number of porcine target assays in the fluorescence channel) to get the porcine target copies per μl in the reaction;
[0209] 2. Calculate the total porcine genome copies in the reaction by multiplying the porcine target copies per μl in the reaction by the reaction volume;
[0210] 3. Divide the total porcine genome copies in the reaction by the volume of DNA sample used in the reaction to obtain the total porcine genome copies per volume of DNA sample;
[0211] 4. multiplying the total porcine genome copies per DNA volume of the sample by the total volume of the DNA sample obtained from the DNA extraction to obtain the total porcine genome copies obtained from the DNA extraction; and
[0212] 5. Calculate the total porcine genome copies per volume of plasma from the recipient by dividing the total porcine genome copies obtained from DNA extraction by the volume of plasma used in the DNA extraction.
[0213] A sequencing-based approach for non-invasive monitoring of cross-species organ transplants
[0214] Library preparation and sequencing
[0215] DNA Prep using Illumina Shotgun libraries were prepared using between 25 ng-100 ng of cfDNA according to the manufacturer's instructions.
[0216] pass The cfDNA kit determined the average library fragment size and the library was quantified by Qubit. The library was sequenced on MiSeq (2×65 or 2×55 cycles, 12pM) or on NextSeq (2×65 or 2×35 cycles, 1.3pM-1.8pM) with paired end reads. Pure human genomic DNA and pure porcine genomic DNA were also sequenced along with artificial samples, with porcine genome equivalents (GE) between 0.2% and 0.4%.
[0217] Bioinformatics
[0218] A next-generation sequencing (NGS) shotgun pipeline was used to analyze sequencing data and quantify the amount of porcine donor-derived cell-free DNA in samples obtained from human recipients of heart transplants donated by engineered pigs and from human deceased model recipients of porcine heart transplants.
[0219] The difference in genome size between the human genome and the genome of a transplant donor animal (e.g., the genome of a genetically modified pig) is accounted for by genome size-based normalization for total reads or by utilizing average coverage of defined bin sizes across the genome, as described in more detail below.
[0220] A combined reference FASTA file consisting of 24 chromosomes of the human genome (UCSC hg19; genome.ucsc.edu / ) and 20 chromosomes of the porcine genome (constituting Sus scrofa 11.1) was created. Raw sequence reads from the FASTQ files were aligned to the combined reference using the BWA aligner. Read alignment was performed with a minimum alignment score cutoff of 90%, an allowed gap percentage of 5%, and without split alignment.
[0221] Various mapping filter models were applied to the filtered aligned reads to determine the estimated bias and stringency (see Table 3). For each model listed in Table 3, the average coverage across 1 megabase (Mb) bins was calculated for the human and porcine genomes. The percentage of cfDNA derived from porcine donors was calculated as: m p / (m p +m h )*100, where m p is the median of the average coverage across a 1Mb region on the pig genome, m h is the median of the average coverage across a 1 Mb region on the human genome. This method takes into account the fact that the pig genome is smaller than the human genome.
[0222] Alternatively, the percentage of cfDNA from porcine donors was calculated by aligning the sequence reads to a combined reference comprising a porcine genome as well as a human genome, and determining the percentage of sequence reads that aligned to the porcine genome as a fraction of the combined reference. This method does not account for the difference in size between the human and porcine genomes.
[0223] In silico samples were prepared at different fractions of the human and porcine genomes with 25 million total sequencing reads to determine the accuracy of the models in Table 3.
[0224] Table 3. Models used to filter aligned reads .
[0225]
[0226]
[0227] Differences in the average fragment sizes of cfDNA from pigs and humans were observed. For example, as shown in Table 4, analysis of two samples containing pig-derived and human-derived cfDNA fragments showed that human-derived cfDNA fragments had longer average fragment sizes. The average cfDNA fragment size difference between pigs and humans (e.g., as shown in Table 4) can lead to an overestimation of the cfDNA fraction of pig donor origin, for example, if smaller cfDNA fragments lead to greater coverage. Therefore, a correction factor can be applied to account for the difference in the average fragment size of pig and human cfDNA to improve accuracy.
[0228] Table 4. Analysis of pig and human cfDNA fragment sizes .
[0229]
[0230] Example 2: Non-Invasive Monitoring of Organ Graft Health in Human Recipients of Porcine Heart Transplants .
[0231] This example describes the non-invasive monitoring of organ graft health in human recipients of porcine heart transplants using the dPCR-based and sequencing-based methods described in Example 1 herein.
[0232] sample
[0233] Blood was collected in two 10 mL Streck tubes from human recipients on days 6, 13, 19, 25, 33, 46, 49, 55, and 60 after they received a transplant of a research heart (UHeart) from a pig that had been genetically modified by Revivicor (a United Therapeutics subsidiary). Cell-free DNA (cfDNA) was extracted using the Qiagen QIAamp circulating nucleic acid kit and quantified using Qubit.
[0234] As shown in Table 5, cfDNA yield varied over time after organ transplantation, from 223 ng on day 25 after transplantation to 3360 ng on day 46 after transplantation.
[0235] Table 5. Patient cfDNA yield .
[0236]
[0237] dPCR-based analysis
[0238] Control samples containing known percentages of control porcine and human genomic DNA were generated to compare the performance of the dPCR assay using either the single copy porcine specific target or the dual copy porcine specific target. As shown in Table 6, the dPCR assay using the dual copy porcine specific target produced up to twice as many positive dPCR partitions as the dPCR assay using the single copy porcine specific target.
[0239] Table 6. Use of a double copy porcine specific target versus a single copy porcine specific target (using a control sample with human and porcine DNA The results of the dPCR assay were compared with .
[0240]
[0241] like Figure 1A and Figure 1B As shown in , a singleplex dPCR assay using a dual copy porcine specific target (see Figure 1A ) and a multiplex dPCR assay using two single copy porcine-specific targets (see Figure 1B ) results in a linear relationship between the known or expected percentage of control porcine DNA and the calculated or measured percentage of porcine DNA. Cell-free DNA (cfDNA) samples from human recipients of porcine heart transplants were analyzed using dPCR at five time points post-transplantation (i.e., days 6, 13, 19, 25, 33, 46, 49, 55, and 60 post-transplantation). Figure 2 As shown, for the genomic copies per mL of plasma sample and the percentage of cell-free DNA derived from porcine donors, the percentage of cell-free DNA derived from porcine donors was the lowest on day 6 after organ transplantation and increased over time until reaching a peak on day 55 after organ transplantation, which then decreased slightly on day 60 after organ transplantation.
[0242] Sequencing-based analysis
[0243] cfDNA samples from human recipients of porcine heart transplants were also analyzed by shotgun next generation sequencing (NGS) using the filtering models M1-M7 as described herein in Example 1 (see Table 3). Control samples containing pure human and porcine genomic DNA were also analyzed using the same method.
[0244] As shown in Table 7, using filter model M7, the pure human DNA control sample had a calculated porcine DNA percentage of 0%, indicating a limit of blank (LOB) very close to zero.
[0245] As described in Table 3 of Example 1 herein, filtering models M1-M7 resulted in estimates of the percentage of cfDNA of different porcine donor origin for samples obtained from human recipients of porcine heart transplants (see Tables 7 and Figure 3 However, all filtering models showed a consistent trend over time, where the percentage of porcine donor-derived cfDNA was lowest on day 6 after organ transplantation and increased over time until reaching a peak on day 55 after organ transplantation, which then decreased slightly on day 60 after organ transplantation (see Tables 7 and Figure 3 ).
[0246] Table 7. DNA from control samples (pure human or porcine genomic DNA samples) and from porcine hearts at the indicated days after transplantation. Shotgun NGS results of patient cfDNA samples from human recipients of transplants
[0247]
[0248] Comparison of the percentage of porcine donor-derived cfDNA calculated using dPCR or shotgun NGS in samples from human recipients of porcine heart transplants using the filter model M7. For the digital PCR assay, a singleplex assay with one two-copy porcine-specific target and one single-copy human-specific target, or a multiplex assay with two single-copy porcine-specific targets and one single-copy human-specific target was used, as described in Table 1.
[0249] like Figure 4 , Figure 5 As shown in Table 8, although the determined percentages of cfDNA derived from porcine donors were generally different between the dPCR method and shotgun NGS, their analysis showed consistent trends over time. Figure 4 As shown, the percentage of cfDNA derived from pig donors was the lowest on day 6 after organ transplantation and peaked on day 55 after organ transplantation, followed by a slight decrease on day 60 after organ transplantation. The percentage of cfDNA derived from pig donors measured by the above-mentioned single-plex dPCR assay with one double-copy pig-specific target and one single-copy human-specific target was half of the percentage of cfDNA derived from pig donors measured by the above-mentioned shotgun NGS method. The percentage of cfDNA derived from pig donors measured by the above-mentioned multiplex dPCR assay with two single-copy pig-specific targets and one single-copy human-specific target was comparable to the percentage of cfDNA derived from pig donors measured by the shotgun NGS method (Table 8).
[0250] Table 8. Comparison of the percentage of cell-free DNA (% xcfDNA) of porcine donor origin in human recipients of porcine heart transplants Comparison %xcfDNA was measured by shotgun next generation sequencing ("NGS"), a singleplex dPCR assay with one two-copy porcine-specific target and one single-copy human-specific target ("singleplex dPCR"), or a multiplex dPCR assay with two single-copy porcine-specific targets and one single-copy human-specific target ("multiplex dPCR").
[0251]
[0252] Example 3: Non-invasive short-term monitoring of organ graft health in recipients of a porcine heart transplant model of human death Test .
[0253] This example describes short-term non-invasive monitoring of organ graft health in two human death model recipients of porcine heart transplants who were temporarily maintained on artificial life support using the sequencing-based and / or multiplex dPCR-based methods described in Example 1.
[0254] sample
[0255] Blood samples from two human death model recipients (Recipient 1 and Recipient 2) were obtained for quantification of porcine donor-derived cell-free DNA. For Recipient 1, blood was collected in two 10 mL Streck tubes at 30, 48, and 72 hours post-transplantation. For Recipient 2, blood was collected in two 10 mL Streck tubes at 0, 12, 24, 36, 48, 60, and 66 hours post-transplantation; however, since the 36-hour and 48-hour samples were indistinguishable due to smearing of the tube labels, they were excluded from further analysis.
[0256] dPCR-based analysis
[0257] Using multiplex dPCR reactions, samples from all available time points were tested in duplicate with either two single copy porcine assays and one single copy human assay ("Multiplex dPCR #1"), or one multicopy porcine assay and one single copy human assay ("Multiplex dPCR #2"). Input cfDNA amounts were 20 ng for the multiplex dPCR #1 test and 10 ng for the multiplex dPCR #2 test. All sample replicates tested with the multiplex dPCR #2 method showed nearly identical % xcfDNA quantification with low standard deviations (Table 9).
[0258] Table 9. In samples from receptor 1 and receptor 2, the expression of dPCR products was detected by multiplex dPCR #1 and multiplex dPCR #2 and NGS methods. Measurement of %xcfDNA, % uncertainty and porcine genome copies per mL plasma .
[0259]
[0260] For both receptors 1 and 2, the %xcfDNA measurements determined by multiplex dPCR #1 and multiplex dPCR #2 were closer to each other than the %xcfDNA measurements by NGS ( Fig. 6A and Figure 6B The porcine genome copies per mL plasma measurements by both dPCR methods were also comparable in the recipient 1 samples ( Figure 6C ) and is almost identical in receptor 2 ( Fig.6D and Table 9).
Claims
1. A method for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient, wherein the donor and the recipient are of different species, said method include: a) providing a sample from the transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and mapping the generated sequence reads to at least the donor-specific genomic sequence, wherein differences in genome size between donors and recipients are accounted for; and c) detecting transplant rejection if the amount of said donor-derived cell-free nucleic acid exceeds a predetermined threshold.
2. The method according to claim 1 further includes adding a quantitative spike nucleic acid control to the sample in step a, wherein sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid.
3. The method of claim 1 or claim 2, wherein the determining step comprises mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences.
4. The method of any one of claims 1 to 3, wherein the sequencing reads are generated from regions of a selected size of the genome.
5. A method according to any one of claims 1 to 4, wherein the size difference between the donor genome and the recipient genome is accounted for by utilizing the average coverage of regions of a selected size across the genome, wherein the regions are large enough to have sufficient coverage and wherein the background noise is low enough to distinguish between the donor and recipient genomes. The method of claim 5 , wherein the size of the region is at most 1 M bases, at most 10 M bases, or at most 100 M bases.
7. The method of any one of claims 1 to 4, wherein the amount of donor-derived cell-free nucleic acid is the average percent coverage of regions of a selected size across the genome, wherein the regions are large enough to have adequate coverage, and wherein background noise is low enough to distinguish between donor and recipient genomes.
8. A method for treating transplant rejection in a recipient of a transplant from a donor, wherein the donor and the recipient are of different species, said method include: a) providing a sample from the transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and mapping the generated sequence reads to at least the donor-specific genomic sequence, wherein differences in genome size between donors and recipients are accounted for; c) detecting transplant rejection if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold; and d) administering an immunosuppressant therapy to the transplant recipient based on the amount of the donor-derived cell-free nucleic acid.
9. The method according to claim 8 further includes adding a quantitative spike nucleic acid control to the sample in step a, wherein sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid.
10. The method of claim 8 or claim 9, wherein the determining step comprises mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences.
11. The method of any one of claims 8 to 10, wherein the sequencing reads are generated from regions of a selected size of the genome.
12. A method according to any one of claims 8 to 11, wherein the size difference between the donor genome and the recipient genome is accounted for by utilizing the average coverage of regions of a selected size across the genome, wherein the regions are large enough to have sufficient coverage and wherein the background noise is low enough to distinguish between the donor and recipient genomes.
13. The method of claim 12, wherein the size of the region is at most 1 M bases, at most 10 M bases, or at most 100 M bases.
14. The method of any one of claims 8 to 11, wherein the amount of donor-derived cell-free nucleic acid is the average percent coverage of a region of a selected size across the genome, wherein the region is large enough to have adequate coverage, and wherein background noise is low enough to distinguish between donor and recipient genomes.
15. A method for adjusting immunosuppressive therapy in a recipient of a transplant from a donor, wherein the donor and the recipient are of different species, said method include: a) providing a sample from the transplant recipient after transplantation, the sample comprising cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample in a high-throughput sequencing assay by generating sequence reads from the cell-free nucleic acid, wherein the generated sequence reads correspond to donor-specific and recipient-specific genomic sequences, and mapping the generated sequence reads to at least the donor-specific genomic sequence, wherein differences in genome size between donors and recipients are accounted for; c) detecting transplant rejection if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold; and d) adjusting immunosuppressant therapy administered to the transplant recipient based on the amount of the donor-derived cell-free nucleic acid.
16. The method of claim 15, further comprising adding a quantitative spike nucleic acid control to the sample in step a, wherein sequence reads from the spike control are used to determine the absolute amount of donor-derived cell-free nucleic acid.
17. The method of claim 15 or claim 16, wherein the determining step comprises mapping the generated sequence reads to donor-specific and recipient-specific genomic sequences.
18. The method of any one of claims 15 to 17, wherein sequencing reads are generated from regions of a selected size of the genome.
19. A method according to any one of claims 15 to 18, wherein the size difference between the donor genome and the recipient genome is accounted for by taking the average coverage of regions of a selected size across the genome, where the regions are large enough to have sufficient coverage and where the background noise is low enough to distinguish between the donor and recipient genomes.
20. The method of claim 19, wherein the size of the region is at most 1 M bases, at most 10 M bases, or at most 100 M bases.
21. The method of any one of claims 15 to 18, wherein the amount of donor-derived cell-free nucleic acid is the average percent coverage of a region of a selected size across the genome, wherein the region is large enough to have adequate coverage, and wherein background noise is low enough to distinguish between donor and recipient genomes.
22. The method of any one of claims 1 to 21, wherein the high-throughput sequencing assay comprises a next generation sequencing assay.
23. A method for detecting and monitoring the transplant rejection state of a transplant from a donor in a transplant recipient, wherein the donor and the recipient are of different species, said method include: a) providing a sample from the transplant recipient after transplantation, wherein the sample comprises cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of donor-derived cell-free nucleic acid is determined as: (i) an absolute number of copies of the donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid; and c) detecting transplant rejection if the amount of said donor-derived cell-free nucleic acid exceeds a predetermined threshold.
24. The method of claim 23, wherein the PCR assay is a quantitative PCR (qPCR) assay and the PCR quantification is a real-time PCR quantification.
25. The method of claim 23, wherein the PCR assay is a digital PCR assay and the PCR quantification is an endpoint PCR quantification.
26. The method of claim 25, wherein the digital PCR assay include: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome.
27. A method according to claim 25, wherein the digital PCR assay comprises at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or acceptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific targets is associated with a haploid donor genome, and the copy number of the acceptor-specific targets is associated with a haploid acceptor genome.
28. The method of claim 26, wherein the digital PCR assay comprises a first singleplex digital PCR assay and a second singleplex digital PCR assay, in: (a) said first singleplex digital PCR assay is directed to a single copy or multiple copies of a receptor-specific target, wherein said copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) said second singleplex digital PCR assay is directed to a single copy or multiple copies of a donor-specific target, wherein said copy number of said donor-specific target is associated with a haploid donor genome.
29. The method of claim 28, wherein the second single-plex digital PCR assay is directed to a multi-copy donor-specific target.
30. The method of claim 27, wherein the multiplex digital PCR assay is for: (a) at least one single copy or multiple copies of a receptor-specific target, wherein the copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) at least one single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
31. The method of claim 27 or claim 30, wherein the multiplex digital PCR assay is directed to at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
32. A method for treating transplant rejection of a transplant from a donor in a transplant recipient, wherein the donor and the recipient are of different species, said method include: a) providing a sample from the transplant recipient after transplantation, wherein the sample comprises cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of donor-derived cell-free nucleic acid is determined as: (i) an absolute number of copies of the donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid; c) detecting transplant rejection if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold; as well as d) administering an immunosuppressant therapy to the transplant recipient based on the amount of the donor-derived cell-free nucleic acid.
33. The method of claim 32, wherein the PCR assay is a quantitative PCR (qPCR) assay and the PCR quantification is real-time PCR quantification.
34. The method of claim 32, wherein the PCR assay is a digital PCR assay and the PCR quantification is an endpoint PCR quantification.
35. The method of claim 34, wherein the digital PCR assay include: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome.
36. A method according to claim 34, wherein the digital PCR assay comprises at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or acceptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific targets is associated with a haploid donor genome, and the copy number of the acceptor-specific targets is associated with a haploid acceptor genome.
37. The method of claim 35, wherein the digital PCR assay comprises a first singleplex digital PCR assay and a second singleplex digital PCR assay, in: (a) said first singleplex digital PCR assay is directed to a single copy or multiple copies of a receptor-specific target, wherein said copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) said second singleplex digital PCR assay is directed to a single copy or multiple copies of a donor-specific target, wherein said copy number of said donor-specific target is associated with a haploid donor genome.
38. The method of claim 37, wherein the second single-plex digital PCR assay is directed to a multi-copy donor-specific target.
39. The method of claim 36, wherein the multiplex digital PCR assay is for: (a) at least one single copy or multiple copies of a receptor-specific target, wherein the copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) at least one single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
40. The method of claim 36 or claim 39, wherein the multiplex digital PCR assay is directed to at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
41. A method for adjusting immunosuppressive therapy in a recipient of a transplant from a donor, wherein the donor and the recipient are of different species, the method include: a) providing a sample from the transplant recipient after transplantation, wherein the sample comprises cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by PCR assay, wherein by PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of donor-derived cell-free nucleic acid is determined as: (i) an absolute number of copies of the donor-derived cell-free nucleic acid in the sample, or (ii) the ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid; c) detecting transplant rejection if the amount of donor-derived cell-free nucleic acid exceeds a predetermined threshold; and d) adjusting immunosuppressant therapy administered to the transplant recipient based on the amount of the donor-derived cell-free nucleic acid.
42. The method of claim 41, wherein the PCR assay is a quantitative PCR (qPCR) assay and the PCR quantification is real-time PCR quantification.
43. The method of claim 41, wherein the PCR assay is a digital PCR assay and the PCR quantification is an endpoint PCR quantification.
44. The method of claim 43, wherein the digital PCR assay include: (a) at least a single-plex digital PCR assay for a single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome; and / or (b) at least a single-plex digital PCR assay for a single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid receptor genome.
45. A method according to claim 43, wherein the digital PCR assay comprises at least a multiplex digital PCR assay for two or more single-copy or multi-copy donor-specific targets and / or acceptor-specific targets in a single digital PCR reaction, wherein the copy number of the donor-specific targets is associated with a haploid donor genome, and the copy number of the acceptor-specific targets is associated with a haploid acceptor genome.
46. The method of claim 44, wherein the digital PCR assay comprises a first singleplex digital PCR assay and a second singleplex digital PCR assay, in: (a) said first singleplex digital PCR assay is directed to a single copy or multiple copies of a receptor-specific target, wherein said copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) said second singleplex digital PCR assay is directed to a single copy or multiple copies of a donor-specific target, wherein said copy number of said donor-specific target is associated with a haploid donor genome.
47. The method of claim 46, wherein the second single-plex digital PCR assay is directed to a multi-copy donor-specific target.
48. The method of claim 45, wherein the multiplex digital PCR assay is for: (a) at least one single copy or multiple copies of a receptor-specific target, wherein the copy number of said receptor-specific target is associated with a haploid receptor genome, and (b) at least one single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
49. The method of claim 45 or claim 48, wherein the multiplex digital PCR assay is directed against at least one multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
50. The method of any one of claims 1 to 49, wherein the method further comprises testing for the presence of an infectious agent.
51. The method of claim 50, wherein the infectious agent is selected from the group consisting of viruses, bacteria, fungi, and parasites.
52. The method of claim 51, wherein the infectious agent is a virus selected from the group consisting of cytomegalovirus, Epstein-Barr virus, Anelloviridae, and BK virus.
53. The method of any one of claims 1 to 52, wherein the method further comprises performing one or more gene expression profiling assays in the receptor.
54. The method of claim 53, wherein a combined score is calculated based on the amount of the donor-derived cell-free nucleic acid in the sample and the results of the gene expression profiling assay.
55. A kit for detecting and monitoring the transplant rejection status of a transplant from a donor in a transplant recipient, wherein the donor and the recipient are of different species, the kit include: (a) one or more PCR reaction oligonucleotide primer and probe sets that hybridize to donor-specific or recipient-specific target sequences in cell-free nucleic acid in a sample from said transplant recipient for PCR quantification of donor-derived cell-free nucleic acid as absolute copies of donor-derived cell-free nucleic acid in said sample, or as a ratio of donor-derived cell-free nucleic acid to total donor-derived and recipient-derived cell-free nucleic acid in said sample; as well as (b) Instructions for data analysis for determining the amount of donor-derived cell-free nucleic acid.
56. The kit of claim 55, wherein the PCR quantification is qPCR quantification.
57. The kit of claim 55, wherein the PCR quantification is digital PCR quantification.
58. The method of any one of claims 1 to 54, or the kit of any one of claims 55 to 57, wherein the donor-derived cell-free nucleic acid and / or the recipient-derived cell-free nucleic acid is DNA.
59. The method of any one of claims 1 to 54, or the kit of any one of claims 55 to 57, wherein the donor-derived cell-free nucleic acid and / or the recipient-derived cell-free nucleic acid is DNA, RNA, mRNA, miRNA, double-stranded DNA, single-stranded DNA, single-stranded DNA hairpin, DNA / RNA hybrid, RNA hairpin, or a combination thereof.
60. The method of any one of claims 1 to 22 and 58 to 59, wherein the amount of the donor-derived cell-free nucleic acid is adjusted with a correction factor that corrects for differences in genome length between the donor genome and the recipient genome.
61. The method of any one of claims 1 to 22 and 58 to 60, wherein the amount of the donor-derived cell-free nucleic acid is adjusted with a correction factor that corrects for differences in cell-free nucleic acid fragment size between the cell-free nucleic acid derived from the donor and the cell-free nucleic acid derived from the recipient.
62. The method of any one of claims 1 to 54 and 58 to 61, or the kit of any one of claims 55 to 59, wherein the amount of donor-derived cell-free nucleic acid is a ratio of donor-derived cell-free nucleic acid to total or recipient-derived cell-free nucleic acid.
63. The method of any one of claims 1 to 54 and 58 to 61, or the kit of any one of claims 55 to 59, wherein the amount of donor-derived cell-free nucleic acid is a percentage of donor-derived cell-free nucleic acid compared to total cell-free nucleic acid.
64. The method of any one of claims 1 to 54 and 58 to 63, or the kit of any one of claims 55 to 59 and 62 to 63, wherein the transplant is a solid organ, tissue or cell transplant.
65. The method or kit of claim 64, wherein the donor of the transplant is an animal.
66. The method or kit of claim 65, wherein the animal is a pig.
67. The method of claim 22, wherein the next generation sequencing assay is amplicon based.
68. The method of claim 22, wherein the next generation sequencing assay is non-amplicon based.
69. A method for analyzing a biological sample from a transplant recipient receiving a solid organ transplant from a donor, wherein the donor and the recipient are of different species, the method include: a) isolating cell-free nucleic acid from a biological sample from the transplant recipient, wherein the cell-free nucleic acid comprises cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) generating amplicons by amplifying target regions of the cell-free nucleic acid, wherein the target regions include one or more target regions comprising donor-specific nucleotide sequences and / or one or more target regions comprising acceptor-specific nucleotide sequences; c) generating sequence reads from the generated amplicons by sequencing the amplicons, wherein the generated sequence reads include one or more sequence reads corresponding to a donor-specific genomic sequence and / or one or more sequence reads corresponding to a recipient-specific genomic sequence, and optionally mapping the generated sequence reads to at least a donor-specific genomic sequence, optionally wherein differences in genome size between the donor and recipient are accounted for; and c) quantifying the amount of cell-free nucleic acid from the sequence reads generated in the sample.
70. The method of claim 69, wherein the amount of cell-free nucleic acid is the amount of transplant donor-derived cell-free nucleic acid in the sample.
71. The method of claim 69, wherein the amount of cell-free nucleic acid is the amount of total cell-free nucleic acid in the sample.
72. The method according to claim 69 or claim 71 further includes adding one or more quantitative spike nucleic acid controls to the sample, and generating sequence reads corresponding to the one or more spike nucleic acid controls by sequencing the one or more spike nucleic acid controls, wherein the sequence reads corresponding to the spike controls are used to determine the absolute amount of total cell-free nucleic acid in the sample.
73. The method according to claim 69 or claim 70 further includes adding one or more quantitative spike nucleic acid controls to the sample, and generating sequence reads corresponding to the one or more spike nucleic acid controls by sequencing the one or more spike nucleic acid controls, wherein the sequence reads from the spike controls are used to determine the absolute amount of cell-free nucleic acid derived from the transplant donor in the sample.
74. The method of claim 72 or claim 73, wherein the one or more quantitative spike nucleic acid controls are added prior to step a).
75. The method of claim 72 or claim 73, wherein the one or more quantitative spike nucleic acid controls are added after step a).
76. The method of claim 72 or claim 73, wherein the one or more quantitative spike nucleic acid controls are added before and after step a).
77. The method of any one of claims 69 to 76, comprising correcting for differences in genome length between the donor genome and the recipient genome using a correction factor to account for differences in genome size between the donor and recipient.
78. A method for analyzing a biological sample from a transplant recipient receiving a solid organ transplant from a donor, wherein the donor and the recipient are of different species, the method include: a) isolating cell-free nucleic acid from a biological sample from the recipient, wherein the cell-free nucleic acid comprises cell-free nucleic acid derived from the donor and cell-free nucleic acid derived from the recipient; b) determining the amount of donor-derived cell-free nucleic acid in the sample by a digital PCR assay, wherein the digital PCR assay comprises: (i) at least one digital PCR assay for one or more single-copy or multi-copy donor-specific targets, or (ii) at least one digital PCR assay for one or more single-copy or multi-copy receptor-specific targets and one or more single-copy or multi-copy donor-specific targets, wherein the copy number of the donor-specific target is associated with a haploid donor genome, and the copy number of the recipient-specific target is associated with a haploid recipient genome, and Wherein by digital PCR quantification of donor-specific nucleic acid and recipient-specific nucleic acid, the amount of cell-free nucleic acid derived from the donor is determined as: (i) an absolute number of copies of the donor-derived cell-free nucleic acid in the sample, or (ii) The ratio of donor-derived cell-free nucleic acid to total donor-derived and acceptor-derived cell-free nucleic acid.
79. A method according to claim 78, wherein the digital PCR assay comprises (a) a first digital PCR assay for a single copy or multiple copies of a receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid recipient genome, and (b) a second digital PCR assay for a single copy or multiple copies of a donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
80. The method of claim 79, wherein the second digital PCR assay is directed to a multi-copy donor-specific target.
81. The method of claim 78, wherein the digital PCR assay is directed against (a) at least one single-copy or multi-copy receptor-specific target, wherein the copy number of the receptor-specific target is associated with a haploid recipient genome; and (b) at least one single-copy or multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
82. The method of claim 81, wherein the digital PCR assay is directed to a multi-copy donor-specific target, wherein the copy number of the donor-specific target is associated with a haploid donor genome.
